beta-adrenergic drug - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	beta-adrenergic drug	go back to main search page
Accession:	CHEBI:48540	browse the term
Definition:	Any of the drugs that act on beta-adrenergic receptors.
Synonyms:	related_synonym:	beta-adrenergic drugs

show annotations for term's descendants Sort by:
Rat (1629) Mouse (1647) Human (1641) Chinchilla (0) Bonobo (0) Dog (15) Squirrel (0) Pig (8) Green Monkey (0) Naked Mole-rat (0) All
Genes (1629)

(R)-adrenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 1

multiple interactions
increases export

[Epinephrine co-treated with [verlukast results in decreased activity of ABCC1 protein]] results in increased abundance of Glutathione Disulfide; [verlukast results in decreased activity of ABCC1 protein] which promotes the reaction and affects the abundance of Epinephrine metabolite
ABCC1 protein results in increased export of Epinephrine metabolite

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

aconitase 2

increases expression

Epinephrine results in increased expression of ACO2 protein

NCBI chr 7:113,385,677...113,428,794
Ensembl chr 7:113,385,646...113,428,261

G

actinin, alpha 1

increases expression

Epinephrine results in increased expression of ACTN1 protein

NCBI chr 6:98,998,553...99,093,334
Ensembl chr 6:98,998,556...99,093,251

G

adiponectin, C1Q and collagen domain containing

multiple interactions
decreases expression

Sildenafil Citrate inhibits the reaction [Epinephrine results in decreased expression of ADIPOQ protein]; Tadalafil inhibits the reaction [Epinephrine results in decreased expression of ADIPOQ protein]

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenoceptor alpha 1A

multiple interactions
increases activity
affects binding

[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; Epinephrine binds to and results in increased activity of ADRA1A protein
Epinephrine results in increased activity of ADRA1A protein
[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1A protein; Epinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]
Epinephrine binds to ADRA1A protein

PMID:8183249 PMID:15306222 PMID:15672411 PMID:20030735

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1B

multiple interactions
increases activity

[Epinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1B protein; Epinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]

PMID:15306222 PMID:20030735

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor alpha 1D

affects binding
increases activity
multiple interactions

Epinephrine binds to ADRA1D protein
Epinephrine results in increased activity of ADRA1D protein
[Epinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1D protein; Epinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]

PMID:8183249 PMID:15306222 PMID:20030735

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

adrenoceptor alpha 2A

increases activity
multiple interactions

Epinephrine results in increased activity of ADRA2A protein
Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein]
[Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2A protein; Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]

PMID:17341653 PMID:17680988 PMID:20030735 PMID:30737458

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor alpha 2B

multiple interactions

[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2B protein; Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]

PMID:17680988 PMID:20030735

NCBI chr 3:114,585,174...114,589,220
Ensembl chr 3:114,585,169...114,589,355

G

adrenoceptor alpha 2C

multiple interactions

[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2C protein; Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]

PMID:17680988 PMID:20030735

NCBI chr14:75,470,884...75,472,846
Ensembl chr14:75,471,143...75,472,846

G

adrenoceptor beta 1

multiple interactions

[CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Epinephrine
Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]
[Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB1 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]

PMID:8096834 PMID:12010770 PMID:14730417

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
affects response to substance
increases activity

[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; carvedilol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Epinephrine binds to and results in increased activity of ADRB2 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine results in increased phosphorylation of and results in increased localization of ADRB2 protein; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]
[Epinephrine results in increased activity of ADRB2 protein] which results in increased secretion of Histamine
ADRB2 affects the susceptibility to Epinephrine

PMID:1389726 PMID:11164953 PMID:12920204 PMID:14722251 PMID:14730417 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Epinephrine binds to and results in increased activity of ADRB3 protein
[Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB3 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]

PMID:1682311 PMID:7815362 PMID:14730417

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

adenylate kinase 2

decreases expression
multiple interactions

Epinephrine results in decreased expression of AK2 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein

NCBI chr 5:141,308,650...141,364,633
Ensembl chr 5:141,346,063...141,364,632

G

AKT serine/threonine kinase 1

multiple interactions

[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amine oxidase, copper containing 1

multiple interactions
increases activity

Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Dactinomycin inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

aquaporin 7

affects localization
multiple interactions
increases expression

Epinephrine affects the localization of AQP7 protein
INS1 inhibits the reaction [Epinephrine results in increased expression of AQP7 mRNA]

NCBI chr 5:56,171,649...56,186,642
Ensembl chr 5:56,172,519...56,186,642

G

ATP synthase F1 subunit alpha

increases expression

Epinephrine results in increased expression of ATP5F1A protein

NCBI chr18:71,292,406...71,300,342
Ensembl chr18:71,292,374...71,300,794

G

BCL2, apoptosis regulator

increases expression

Epinephrine results in increased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

bone morphogenetic protein 2

decreases expression

Epinephrine results in decreased expression of BMP2 mRNA; Epinephrine results in decreased expression of BMP2 protein

NCBI chr 3:120,812,660...120,822,579
Ensembl chr 3:120,812,882...120,821,397

G

complement C1q binding protein

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein
Epinephrine results in increased expression of C1QBP protein

NCBI chr10:55,699,954...55,704,605
Ensembl chr10:55,699,954...55,704,649

G

calcitonin-related polypeptide alpha

increases abundance

CALCA protein results in increased abundance of Epinephrine

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcyon neuron-specific vesicular protein

decreases secretion

CALY protein results in decreased secretion of Epinephrine

NCBI chr 1:194,862,671...194,873,861
Ensembl chr 1:194,862,672...194,873,551

G

carbonic anhydrase 2

increases expression

Epinephrine results in increased expression of CA2 mRNA

NCBI chr 2:86,741,625...86,756,766
Ensembl chr 2:86,741,626...86,756,818

G

caspase 3

multiple interactions
increases expression
increases activity

Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]; carvedilol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]
Epinephrine results in increased expression of CASP3 protein
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein]; Sildenafil Citrate inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]; Tadalafil inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]; Vardenafil Dihydrochloride inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]

PMID:10728402 PMID:19135123 PMID:29233027

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases response to substance

CAT results in decreased susceptibility to Epinephrine

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 3

multiple interactions

Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]; Propranolol inhibits the reaction [Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]]
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Epinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]

PMID:9863660 PMID:12538206

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

cyclin D1

multiple interactions
increases expression

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; 2-methoxyidazoxan inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]
Epinephrine results in increased expression of CCND1 mRNA; Epinephrine results in increased expression of CCND1 protein
ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]

PMID:17680988 PMID:26964897

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

CCAAT/enhancer binding protein beta

decreases expression

Epinephrine results in decreased expression of CEBPB protein

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

cholinergic receptor nicotinic alpha 7 subunit

multiple interactions

[methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased abundance of Epinephrine]

NCBI chr 1:116,711,559...116,837,269
Ensembl chr 1:116,714,711...116,837,240

G

catechol-O-methyltransferase

increases methylation
multiple interactions

COMT protein results in increased methylation of Epinephrine
[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine]
[tolcapone results in decreased activity of COMT protein] which results in increased abundance of Epinephrine

PMID:8821542 PMID:10064789 PMID:11160877 PMID:11248589

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

cAMP responsive element binding protein 1

multiple interactions
increases phosphorylation

ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Dietary Fats promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Epinephrine promotes the reaction [Dietary Fats results in increased phosphorylation of CREB1 protein]; Ketoconazole inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]

PMID:17680988 PMID:22496244

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

multiple interactions
increases abundance

corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Epinephrine]
CRH results in increased abundance of Epinephrine

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

C-terminal Src kinase

multiple interactions

CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]]

NCBI chr 8:58,029,748...58,048,742
Ensembl chr 8:58,029,749...58,048,292

G

catenin beta 1

increases phosphorylation
multiple interactions

Epinephrine results in increased phosphorylation of CTNNB1 protein
N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cathepsin K

increases expression

Epinephrine results in increased expression of CTSK mRNA

NCBI chr 2:183,058,586...183,069,551
Ensembl chr 2:183,058,569...183,069,550

G

cytochrome c, somatic

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein
Epinephrine results in increased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

dopamine beta-hydroxylase

affects abundance

DBH gene polymorphism affects the abundance of Epinephrine

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

desmin

multiple interactions
decreases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein
Epinephrine results in decreased expression of DES protein

NCBI chr 9:76,850,979...76,858,695
Ensembl chr 9:76,850,982...76,858,699

G

dihydrolipoamide S-acetyltransferase

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein

NCBI chr 8:50,979,151...51,004,435
Ensembl chr 8:50,978,051...51,004,479
Ensembl chr 1:50,978,051...51,004,479

G

enoyl-CoA hydratase, short chain 1

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein

NCBI chr 1:194,895,036...194,903,863
Ensembl chr 1:194,895,036...194,903,884

G

Eph receptor A4

increases phosphorylation

Epinephrine results in increased phosphorylation of EPHA4 protein

NCBI chr 9:78,815,460...78,958,139
Ensembl chr 9:78,815,460...78,958,139

G

electron transfer flavoprotein subunit beta

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein

NCBI chr 1:93,851,908...93,866,072
Ensembl chr 1:93,851,858...93,866,068

G

fatty acid binding protein 3

affects expression
multiple interactions

Epinephrine affects the expression of FABP3 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:142,651,956...142,658,718

G

Fas cell surface death receptor

multiple interactions
increases expression

Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
increases expression

Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fumarate hydratase

increases expression

Epinephrine results in increased expression of FH protein

NCBI chr13:87,524,331...87,550,215
Ensembl chr13:87,524,337...87,550,266

G

forkhead box O1

decreases expression

Epinephrine results in decreased expression of FOXO1 protein

NCBI chr 2:136,312,168...136,390,603
Ensembl chr 2:136,312,168...136,387,790

G

G protein subunit beta 2

multiple interactions

Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein]

NCBI chr12:19,159,002...19,164,021
Ensembl chr12:19,158,973...19,164,019

G

G protein subunit beta 4

multiple interactions

Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein]

NCBI chr 2:115,360,746...115,400,680
Ensembl chr 2:115,364,918...115,400,579

G

G protein subunit gamma 12

multiple interactions

Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein]

NCBI chr 4:96,011,118...96,134,767
Ensembl chr 4:96,010,952...96,134,712

G

G protein subunit gamma 2

multiple interactions

Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein]

NCBI chr15:4,316,038...4,416,918
Ensembl chr15:4,316,059...4,417,183

G

G protein subunit gamma 3

multiple interactions

Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein]

NCBI chr 1:205,731,837...205,733,603
Ensembl chr 1:205,731,837...205,733,603

G

G protein subunit gamma 4

multiple interactions

Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein]

NCBI chr17:86,448,708...86,497,560
Ensembl chr17:86,449,022...86,495,254

G

G protein-coupled receptor kinase 2

multiple interactions

Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein]

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

G protein-coupled receptor kinase 5

multiple interactions

Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein]

NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701

G

hydroxyacyl-CoA dehydrogenase

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein

NCBI chr 2:219,787,935...219,830,335
Ensembl chr 2:219,787,927...219,830,353

G

hypoxia inducible factor 1 subunit alpha

increases expression

Epinephrine results in increased expression of HIF1A protein

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

hexokinase 2

increases expression

Epinephrine results in increased expression of HK2 protein

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

heat shock transcription factor 1

multiple interactions
affects localization

Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein]
Epinephrine affects the localization of HSF1 protein

NCBI chr 7:108,196,040...108,223,011
Ensembl chr 7:108,196,056...108,223,011

G

heat shock protein 90 alpha family class B member 1

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein

NCBI chr 9:15,432,986...15,438,358
Ensembl chr 9:15,433,691...15,438,488

G

heat shock protein family A (Hsp70) member 5

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

increases expression

Epinephrine results in increased expression of HSPA8 protein

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family A (Hsp70) member 9

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein

NCBI chr18:26,536,131...26,554,294
Ensembl chr18:26,535,798...26,554,292

G

heat shock protein family B (small) member 6

decreases expression
multiple interactions

Epinephrine results in decreased expression of HSPB6 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein

NCBI chr 1:85,806,898...85,809,072
Ensembl chr 1:85,806,146...85,809,071

G

isocitrate dehydrogenase (NADP(+)) 2

decreases expression
multiple interactions

Epinephrine results in decreased expression of IDH2 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein

NCBI chr 1:134,038,644...134,057,969
Ensembl chr 1:134,029,772...134,058,025

G

interleukin 10

multiple interactions

Epinephrine promotes the reaction [Lipopolysaccharides results in increased expression of IL10 protein]

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

multiple interactions

Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression
multiple interactions

Epinephrine results in decreased expression of IL6 mRNA
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

PMID:10588509 PMID:12423672

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

INS1 inhibits the reaction [Epinephrine results in increased expression of AQP7 mRNA]
cilostamide inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; Cytochalasin B inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]; Wortmannin inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]

PMID:10777495 PMID:15172182

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions
decreases expression

[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein; Butoxamine inhibits the reaction [Epinephrine results in decreased expression of INS protein]; Pentolinium Tartrate inhibits the reaction [Epinephrine results in decreased secretion of INS protein]; Propranolol inhibits the reaction [Epinephrine results in decreased expression of INS protein]

PMID:1218171 PMID:6018752 PMID:6314140 PMID:32305330

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

integrin subunit alpha 2

multiple interactions

ITGA2 gene SNP affects the susceptibility to [Aspirin co-treated with clopidogrel co-treated with Epinephrine]

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:46,523,948...46,621,481

G

integrin subunit alpha V

increases expression

Epinephrine results in increased expression of ITGAV mRNA

NCBI chr 3:68,838,514...68,926,653
Ensembl chr 3:68,838,189...68,926,639

G

integrin subunit beta 1

increases response to substance

ITGB1 results in increased susceptibility to Epinephrine

NCBI chr19:56,705,123...56,753,199
Ensembl chr19:56,705,171...56,753,195

G

lipase E, hormone sensitive type

multiple interactions
increases expression
affects localization
increases activity

Theophylline inhibits the reaction [Epinephrine results in increased activity of LIPE protein]
Epinephrine results in increased expression of LIPE mRNA
Epinephrine affects the localization of LIPE protein

PMID:7155675 PMID:10777495 PMID:11160373

NCBI chr 1:80,965,612...80,984,313
Ensembl chr 1:80,965,627...80,984,310

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation
increases activity
affects activity

ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]
Epinephrine deficiency results in increased activity of MAPK1 protein
Epinephrine affects the activity of MAPK1 protein

PMID:11093795 PMID:15292328 PMID:17680988 PMID:22496244

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation
increases activity
affects activity

ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]
Epinephrine deficiency results in increased activity of MAPK3 protein
Epinephrine affects the activity of MAPK3 protein

PMID:11093795 PMID:15292328 PMID:17680988 PMID:22496244

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

Meis homeobox 1

decreases expression

Epinephrine results in decreased expression of MEIS1 protein

NCBI chr14:93,155,426...93,294,373
Ensembl chr14:93,155,419...93,294,265

G

myosin light chain 2

multiple interactions
affects expression

[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein
Epinephrine affects the expression of MYL2 protein

NCBI chr12:34,454,223...34,468,554
Ensembl chr12:34,454,218...34,468,983

G

neurofilament heavy chain

affects expression

Epinephrine affects the expression of NEFH mRNA

NCBI chr14:79,830,362...79,840,347
Ensembl chr14:79,830,362...79,840,351

G

nuclear factor kappa B subunit 1

multiple interactions

Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions
increases expression

Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
Epinephrine results in increased expression of NOS2 mRNA

PMID:16925470 PMID:19439816

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

neurotrophin 3

increases expression

Epinephrine results in increased expression of NTF3 mRNA; Epinephrine results in increased expression of NTF3 protein

NCBI chr 4:158,914,984...158,984,453
Ensembl chr 4:158,914,957...158,984,596

G

purinergic receptor P2X 7

decreases activity

Epinephrine results in decreased activity of P2RX7 protein

NCBI chr12:33,889,709...33,934,168
Ensembl chr12:33,879,745...33,934,619

G

purinergic receptor P2Y12

multiple interactions

Epinephrine inhibits the reaction [P2RY12 gene mutant form results in decreased susceptibility to Adenosine Diphosphate]

NCBI chr 2:143,481,468...143,523,340
Ensembl chr 2:143,481,430...143,523,361

G

poly (ADP-ribose) polymerase 1

decreases cleavage

Epinephrine results in decreased cleavage of PARP1 protein

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

proliferating cell nuclear antigen

increases expression

Epinephrine results in increased expression of PCNA protein

NCBI chr 3:119,499,039...119,502,911
Ensembl chr 3:119,498,810...119,502,995

G

prohibitin 1

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB1 protein
Epinephrine results in increased expression of PHB1 protein

NCBI chr10:80,605,268...80,618,043
Ensembl chr10:80,605,251...80,618,042

G

phosphoglycerate dehydrogenase

increases expression

Epinephrine results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

pyruvate kinase M1/2

multiple interactions
increases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein
Epinephrine results in increased expression of PKM protein

PMID:19464573 PMID:36423730

NCBI chr 8:60,057,629...60,079,600
Ensembl chr 8:60,057,402...60,079,599

G

PPARG coactivator 1 alpha

increases expression

Epinephrine results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein phosphatase 2 scaffold subunit A alpha

decreases expression
multiple interactions

Epinephrine results in decreased expression of PPP2R1A protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein

NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129

G

peroxiredoxin 6

multiple interactions
decreases expression

[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein
Epinephrine results in decreased expression of PRDX6 protein

NCBI chr13:73,528,746...73,539,295
Ensembl chr13:73,528,210...73,539,355

G

protein kinase C, epsilon

affects response to substance

PRKCE protein affects the susceptibility to Epinephrine

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

prostaglandin-endoperoxide synthase 2

decreases expression

Epinephrine results in decreased expression of PTGS2 mRNA; Epinephrine results in decreased expression of PTGS2 protein

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

multiple interactions
increases activity

ICI 118551 inhibits the reaction [Epinephrine results in increased activity of REN protein]

PMID:6314140 PMID:8592096

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

secretin

multiple interactions

Epinephrine inhibits the reaction [SCT protein results in increased abundance of Cyclic AMP]

NCBI chr 1:196,382,857...196,383,668
Ensembl chr 1:196,382,856...196,383,658

G

serpin family E member 1

increases expression

Epinephrine results in increased expression of SERPINE1 mRNA

NCBI chr12:19,601,272...19,611,657
Ensembl chr12:19,601,272...19,611,657

G

solute carrier family 22 member 3

multiple interactions
increases uptake

[Corticosterone results in decreased activity of SLC22A3 protein] inhibits the reaction [Epinephrine results in increased abundance of Epinephrine metabolite]; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased abundance of Epinephrine
SLC22A3 protein results in increased uptake of Epinephrine

PMID:19053318 PMID:20858707

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

solute carrier family 29 member 4

increases uptake

SLC29A4 protein results in increased uptake of Epinephrine

NCBI chr12:11,853,540...11,884,660
Ensembl chr12:11,853,540...11,874,834

G

superoxide dismutase 1

multiple interactions
affects binding
increases expression
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]
Epinephrine binds to SOD1 protein mutant form
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein
Epinephrine results in increased expression of SOD1 protein
Epinephrine results in increased expression of SOD1 mRNA; Epinephrine results in increased expression of SOD1 protein

PMID:11163531 PMID:19464573 PMID:23612299

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
increases expression
increases activity

6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein
Epinephrine results in increased expression of SOD2 protein
Epinephrine results in increased expression of SOD2 mRNA; Epinephrine results in increased expression of SOD2 protein

PMID:11163531 PMID:19464573

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

succinate-CoA ligase GDP-forming subunit beta

increases expression

Epinephrine results in increased expression of SUCLG2 protein

NCBI chr 4:128,067,031...128,337,146
Ensembl chr 4:128,067,033...128,337,170

G

tyrosine hydroxylase

increases chemical synthesis
multiple interactions

TH protein results in increased chemical synthesis of Epinephrine
[Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine

PMID:9822156 PMID:19067675

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

Thy-1 cell surface antigen

multiple interactions
decreases expression

Propranolol inhibits the reaction [Epinephrine results in decreased expression of THY1]

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

tumor necrosis factor

multiple interactions
decreases expression
decreases secretion

Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]
Epinephrine results in decreased expression of TNF mRNA
Epinephrine results in decreased secretion of TNF protein

PMID:10588509 PMID:12423672

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression

Epinephrine results in decreased expression of TP53 protein

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

voltage-dependent anion channel 1

increases expression
multiple interactions

Epinephrine results in increased expression of VDAC1 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

Wnt family member 4

decreases expression

Epinephrine results in decreased expression of WNT4 mRNA; Epinephrine results in decreased expression of WNT4 protein

NCBI chr 5:149,513,573...149,535,415
Ensembl chr 5:149,514,018...149,532,859

G

xanthine dehydrogenase

multiple interactions

[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein]

PMID:19135123 PMID:19464573

NCBI chr 6:21,530,463...21,592,172
Ensembl chr 6:21,530,113...21,592,268

(S)-timolol (anhydrous)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

Timolol binds to and results in decreased activity of ADRB1 protein; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]

PMID:11436944 PMID:15060759

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[Timolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Timolol binds to and results in decreased activity of ADRB2 protein

PMID:11436944 PMID:17925438

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

amine oxidase, copper containing 1

multiple interactions

Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]

NCBI chr 4:77,812,260...77,831,846
Ensembl chr 4:77,812,260...77,831,840

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects response to substance

CYP2D6 gene SNP affects the susceptibility to Timolol

PMID:19284319 PMID:20925579

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

mitogen activated protein kinase 1

multiple interactions

[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]

PMID:11914123 PMID:18977218

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]
1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]

PMID:11914123 PMID:18977218

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

regulator of G-protein signaling 3

multiple interactions

RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr 5:76,022,038...76,161,895
Ensembl chr 5:76,022,001...76,161,894

G

regulator of G-protein signaling 4

multiple interactions

RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS4 protein affects the reaction [[Timolol co-treated with Phenylephrine] results in increased phosphorylation of and results in increased activity of MAPK3 protein]

NCBI chr13:81,936,775...81,943,103
Ensembl chr13:81,936,775...81,943,068

2-O-acetyl-1-O-octadecyl-sn-glycero-3-phosphocholine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

tumor necrosis factor

increases expression

platelet-activating factor increases expression of Tnf protein in portal stenosis rat plasma

RGD

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

3-methoxytyramine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

trace-amine-associated receptor 1

increases activity
multiple interactions

3-methoxytyramine results in increased activity of TAAR1 protein
[3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

G

vitamin D receptor

multiple interactions
increases abundance

Calcitriol promotes the reaction [VDR protein results in increased abundance of 3-methoxytyramine]

NCBI chr 7:128,987,981...129,037,677
Ensembl chr 7:128,987,981...129,037,677

4-methoxytyramine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

trace-amine-associated receptor 1

increases activity
multiple interactions

3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein
[3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP

NCBI chr 1:21,517,742...21,518,740
Ensembl chr 1:21,517,258...21,532,084

acebutolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions
increases activity

[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; CGP 20712A inhibits the reaction [[Acebutolol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Acebutolol results in increased activity of ADRB1 protein]

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[Acebutolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

Fos proto-oncogene, AP-1 transcription factor subunit

increases expression

Acebutolol results in increased expression of FOS mRNA

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

mitogen activated protein kinase 1

multiple interactions

[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Acebutolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

renin

decreases activity

Acebutolol results in decreased activity of REN protein

PMID:6110712 PMID:6118215

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

adrenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

serpin family F member 1

multiple interactions

epinephrine promotes the reaction [lipopolysaccharide increases expression of Serpinf1 protein in plasma]

RGD

NCBI chr10:60,250,198...60,262,593
Ensembl chr10:60,249,708...60,262,646

albuterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

increases expression
multiple interactions

Albuterol results in increased expression of ABCB11 mRNA
Carvedilol inhibits the reaction [Albuterol results in increased expression of ABCB11 mRNA]

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adrenoceptor beta 1

multiple interactions

Albuterol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Albuterol inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]

PMID:8096834 PMID:14730417

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

decreases response to substance
increases activity
multiple interactions
increases phosphorylation
decreases expression

ADRB2 gene polymorphism results in decreased susceptibility to Albuterol
Albuterol results in increased activity of ADRB2 protein
[Albuterol binds to and results in increased activity of ADRB2 protein] which results in decreased abundance of Potassium; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein; [Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein; Albuterol binds to and results in increased activity of ADRB2 protein; Albuterol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; ICI 118551 inhibits the reaction [Albuterol results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]
Albuterol results in increased phosphorylation of ADRB2 protein
[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Hydroxyindoleacetic Acid; Albuterol binds to and results in increased activity of ADRB2 protein
Albuterol results in decreased expression of ADRB2 protein

PMID:2463453 PMID:8102213 PMID:8937731 PMID:10516654 PMID:10952688 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

[Albuterol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Albuterol binds to and results in increased activity of ADRB3 protein; Albuterol inhibits the reaction [cyanopindolol binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

BCL2 associated X, apoptosis regulator

increases expression

Albuterol results in increased expression of BAX

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Albuterol results in decreased expression of BCL2

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

catalase

multiple interactions

CAT protein inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 3

multiple interactions

Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

C-C motif chemokine ligand 5

multiple interactions

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

CD44 molecule

multiple interactions

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]

NCBI chr 3:89,155,850...89,244,615
Ensembl chr 3:89,157,058...89,244,620

G

cyclin dependent kinase 2

increases expression

Albuterol results in increased expression of CDK2 protein

NCBI chr 7:1,129,878...1,137,431
Ensembl chr 7:1,129,811...1,137,403

G

cyclin-dependent kinase 4

increases expression

Albuterol results in increased expression of CDK4 protein

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

creatine kinase, M-type

increases secretion

Albuterol results in increased secretion of CKM protein

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

colony stimulating factor 2

multiple interactions

[Beclomethasone co-treated with Albuterol] results in decreased secretion of CSF2 protein

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome P450, family 17, subfamily a, polypeptide 1

increases expression

Albuterol results in increased expression of CYP17A1

NCBI chr 1:245,535,462...245,543,148
Ensembl chr 1:245,535,462...245,541,573

G

cytochrome P450, family 19, subfamily a, polypeptide 1

multiple interactions

[Cyproterone co-treated with Albuterol] results in decreased expression of CYP19A1

NCBI chr 8:54,552,978...54,580,375
Ensembl chr 8:54,553,165...54,580,758

G

fibroblast growth factor 2

multiple interactions

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of CD44 protein]]; Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]; Albuterol promotes the reaction [Beclomethasone results in decreased activity of FGF2 protein]

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

fibronectin 1

multiple interactions

[Beclomethasone co-treated with Albuterol] inhibits the reaction [FGF2 protein results in increased secretion of FN1 protein]

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

glucose-6-phosphate dehydrogenase

increases activity

Albuterol results in increased activity of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

insulin-like growth factor 1

affects expression

Albuterol affects the expression of IGF1 mRNA

NCBI chr 7:22,282,895...22,361,972
Ensembl chr 7:22,282,930...22,359,296

G

interleukin 10

decreases expression

Albuterol results in decreased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

decreases expression

Albuterol results in decreased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

multiple interactions
decreases expression

Albuterol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]
Albuterol results in decreased expression of IL1B mRNA

PMID:11112151 PMID:32816093

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 24

increases expression

Albuterol results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 4

multiple interactions

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [IL4 protein results in decreased expression of CD44 protein]]

NCBI chr10:37,771,203...37,776,750
Ensembl chr10:37,771,203...37,776,750

G

interleukin 5

multiple interactions

1-Methyl-3-isobutylxanthine promotes the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]; Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]; ICI 118551 inhibits the reaction [Albuterol inhibits the reaction [IL5 protein results in increased abundance of Superoxides]]

NCBI chr10:37,874,342...37,877,213
Ensembl chr10:37,874,342...37,877,213

G

interleukin 6

increases expression
multiple interactions

Albuterol results in increased expression of IL6 protein
Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
[Albuterol co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [Dexamethasone co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]; [Theophylline co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Albuterol promotes the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Albuterol promotes the reaction [Lipopolysaccharides results in increased secretion of IL6 protein]

PMID:18362475 PMID:20388727 PMID:20519841

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

increases expression

Albuterol results in increased expression of INS; Albuterol results in increased expression of INS protein

PMID:8098220 PMID:9088585

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

low density lipoprotein receptor

affects response to substance

LDLR gene SNP affects the susceptibility to Albuterol

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

mitogen activated protein kinase 1

multiple interactions

[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK1 protein
Albuterol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK1 protein]

PMID:16980553 PMID:20519841

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased phosphorylation of and results in increased activity of MAPK3 protein
Albuterol inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased activity of MAPK3 protein]

PMID:16980553 PMID:20519841

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

myeloperoxidase

multiple interactions

[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol; Ascorbic Acid inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; CAT protein inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Glutathione inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Sodium Azide inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]; Sodium Cyanide inhibits the reaction [[MPO protein co-treated with Hydrogen Peroxide] results in increased oxidation of Albuterol]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mechanistic target of rapamycin kinase

increases expression

Albuterol results in increased expression of MTOR mRNA

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

NFKB inhibitor alpha

increases expression

Albuterol results in increased expression of NFKBIA protein

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

nitric oxide synthase 2

multiple interactions

Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nuclear receptor subfamily 3, group C, member 1

multiple interactions

[Beclomethasone co-treated with Albuterol] affects the localization of NR3C1 protein

NCBI chr18:31,271,681...31,393,320
Ensembl chr18:31,271,681...31,393,375

G

phosphodiesterase 4A

multiple interactions

[Albuterol co-treated with Rolipram] results in increased expression of PDE4A mRNA

NCBI chr 8:19,690,816...19,753,538
Ensembl chr 8:19,703,290...19,751,961

G

phosphodiesterase 4B

multiple interactions

[Albuterol co-treated with Rolipram] results in increased expression of PDE4B mRNA

NCBI chr 5:116,799,819...117,369,155
Ensembl chr 5:116,799,971...117,367,696

G

phosphotyrosine interaction domain containing 1

increases expression

Albuterol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

phosphoinositide-3-kinase regulatory subunit 1

affects expression

Albuterol affects the expression of PIK3R1 mRNA

NCBI chr 2:32,878,942...32,963,668
Ensembl chr 2:32,882,032...32,963,631

G

paraoxonase 1

decreases activity

Albuterol results in decreased activity of PON1 protein

NCBI chr 4:33,294,737...33,325,759
Ensembl chr 4:33,294,722...33,321,360

G

PPARG coactivator 1 alpha

increases expression

Albuterol results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase AMP-activated catalytic subunit alpha 2

increases expression

Albuterol results in increased expression of PRKAA2 mRNA

NCBI chr 5:119,807,992...119,879,987
Ensembl chr 5:119,813,226...119,879,543

G

platelet-activating factor receptor

increases expression

Albuterol results in increased expression of PTAFR protein

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 2

multiple interactions
decreases expression

Albuterol promotes the reaction [IL1B protein results in increased expression of PTGS2 protein]
Albuterol results in decreased expression of PTGS2 mRNA

PMID:11112151 PMID:32816093

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

RB transcriptional corepressor 1

decreases expression
multiple interactions
increases expression

Albuterol results in decreased expression of RB1 protein
ICI 118551 inhibits the reaction [Albuterol results in decreased expression of RB1 protein]
Albuterol results in increased expression of RB1 protein

PMID:16446544 PMID:18362475

NCBI chr15:48,371,295...48,502,473
Ensembl chr15:48,371,296...48,502,302

G

renin

increases expression

Albuterol results in increased expression of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

solute carrier family 10 member 1

multiple interactions
increases expression

[Carvedilol co-treated with Albuterol] results in decreased expression of SLC10A1 protein; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 mRNA]; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 protein]
Albuterol results in increased expression of SLC10A1 mRNA; Albuterol results in increased expression of SLC10A1 protein

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

secretory leukocyte peptidase inhibitor

decreases expression

Albuterol results in decreased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

Thy-1 cell surface antigen

multiple interactions

Albuterol promotes the reaction [Beclomethasone inhibits the reaction [FGF2 protein results in decreased expression of THY1 protein]]

NCBI chr 8:44,389,495...44,394,688
Ensembl chr 8:44,389,513...44,394,659

G

tumor necrosis factor

decreases secretion
multiple interactions

Albuterol results in decreased secretion of TNF protein
[Albuterol co-treated with Theophylline] inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; [Dexamethasone co-treated with Albuterol] inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Albuterol inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]; Albuterol promotes the reaction [Theophylline inhibits the reaction [Lipopolysaccharides results in increased secretion of TNF protein]]

PMID:8937731 PMID:10229875 PMID:20388727 PMID:20519841

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

increases expression

Albuterol results in increased expression of TP53

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

uncoupling protein 1

increases expression

Albuterol results in increased expression of UCP1 protein

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

G

uncoupling protein 3

multiple interactions

[Albuterol co-treated with acipimox] results in decreased expression of UCP3 mRNA

NCBI chr 1:154,815,777...154,828,764
Ensembl chr 1:154,815,777...154,828,762

alprenolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions
increases phosphorylation
increases activity

[Alprenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Alprenolol binds to and results in decreased activity of ADRB1 protein; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; CGP 20712A affects the reaction [Alprenolol results in increased activity of ADRB1 protein]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
[Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein; Alprenolol results in increased phosphorylation of ADRB1 protein

PMID:12761341 PMID:14730417 PMID:15060759 PMID:18787115

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[Alprenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Alprenolol co-treated with ADRB2 protein] results in increased expression of GNAS protein; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]
Alprenolol inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; Alprenolol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein]

PMID:10455254 PMID:12198331 PMID:14730417 PMID:17925438

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

[Alprenolol binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Alprenolol binds to and results in increased activity of ADRB3 protein; Alprenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

arrestin, beta 1

multiple interactions

[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA; [Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA; Alprenolol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

PMID:18787115 PMID:24334028

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions

Alprenolol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

citrate synthase

multiple interactions
increases activity

[POMC protein co-treated with Alprenolol] results in increased activity of CS protein
Alprenolol results in increased activity of CS protein

NCBI chr 7:758,074...791,421
Ensembl chr 7:758,345...791,421

G

epidermal growth factor receptor

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
[Alprenolol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

GNAS complex locus

multiple interactions

[Alprenolol co-treated with ADRB2 protein] results in increased expression of GNAS protein

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

G protein-coupled receptor kinase 2

multiple interactions

Alprenolol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein]

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

heparin-binding EGF-like growth factor

multiple interactions

HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

5-hydroxytryptamine receptor 2A

multiple interactions

[Alprenolol co-treated with Cocaine] affects the reaction [HTR2A protein results in increased susceptibility to 4-iodo-2,5-dimethoxyphenylisopropylamine]

NCBI chr15:49,950,035...50,022,188
Ensembl chr15:49,950,804...50,020,928

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

[Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]

PMID:17925438 PMID:18787115

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

[Alprenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; ARRB1 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]

PMID:17925438 PMID:18787115

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microRNA 125a

multiple interactions
increases expression

[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA
Alprenolol results in increased expression of MIR125A mRNA

NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710

G

microRNA 125b-1

multiple interactions
increases expression

[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA
Alprenolol results in increased expression of MIR125B-1 mRNA

NCBI chr 8:41,952,966...41,953,052
Ensembl chr 8:41,952,966...41,953,052

G

microRNA 150

multiple interactions
increases expression

[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA
Alprenolol results in increased expression of MIR150 mRNA

NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108

G

microRNA 214

increases expression
multiple interactions

Alprenolol results in increased expression of MIR214 mRNA
[Alprenolol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA

NCBI chr13:74,588,374...74,588,481
Ensembl chr13:74,588,372...74,588,481

G

natriuretic peptide A

increases expression

Alprenolol results in increased expression of NPPA mRNA

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

ornithine decarboxylase 1

multiple interactions

Alprenolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

proopiomelanocortin

multiple interactions

[POMC protein co-treated with Alprenolol] results in increased activity of CS protein

NCBI chr 6:26,939,844...26,945,666
Ensembl chr 6:26,939,837...26,945,664

G

renin

multiple interactions
decreases expression

Alprenolol inhibits the reaction [Hydralazine results in increased expression of REN protein]
Alprenolol results in decreased expression of REN protein

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

solute carrier family 22 member 2

multiple interactions

Alprenolol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

arbutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

arbutamine binds to and results in increased activity of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

asenapine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity
decreases expression

Asenapine results in decreased activity of CYP1A2 protein
Asenapine results in decreased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

atenolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases activity

Atenolol inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Atenolol results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adrenoceptor alpha 2A

affects response to substance

ADRA2A gene SNP affects the susceptibility to Atenolol

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 1

decreases activity
multiple interactions
affects binding
affects response to substance
decreases expression

Atenolol results in decreased activity of ADRB1 protein
Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein]
Atenolol binds to ADRB1 protein
[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Atenolol binds to and results in decreased activity of ADRB1 protein] which results in decreased susceptibility to Nicotine; [Atenolol co-treated with ADRB1] results in increased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB1 protein; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]
ADRB1 protein polymorphism affects the susceptibility to Atenolol
Atenolol results in decreased expression of ADRB1 mRNA

PMID:1389726 PMID:2462161 PMID:2897299 PMID:8102213 PMID:8386603 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

increases expression
affects binding
multiple interactions

Atenolol results in increased expression of ADRB2 protein
Atenolol binds to ADRB2 protein
Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Atenolol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein]
[Atenolol binds to ADRB2 protein] which results in increased abundance of Cyclic AMP; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Atenolol binds to and results in decreased activity of ADRB2 protein; Atenolol inhibits the reaction [[Albuterol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Isoproterenol binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Albuterol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Isoproterenol binds to and results in increased activity of ADRB2 protein]; Atenolol inhibits the reaction [Terbutaline binds to and results in increased activity of ADRB2 protein]

PMID:2462161 PMID:6093157 PMID:9593075 PMID:11425575 PMID:11483288 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Atenolol inhibits the reaction [cyanopindolol binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

angiotensinogen

affects response to substance
decreases expression

AGT gene SNP affects the susceptibility to Atenolol
Atenolol results in decreased expression of AGT protein

PMID:14639093 PMID:14700505

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

amylase alpha 1

multiple interactions

Atenolol inhibits the reaction [Apomorphine results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Cisplatin results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Isoproterenol results in increased secretion of and results in increased activity of AMY1A protein]; Atenolol inhibits the reaction [Lithium Chloride results in increased secretion of and results in increased activity of AMY1A protein]

NCBI chr 2:201,382,678...201,397,487
Ensembl chr 2:201,382,675...201,397,816

G

apolipoprotein A1

decreases expression

Atenolol results in decreased expression of APOA1 protein

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

apolipoprotein A2

decreases expression

Atenolol results in decreased expression of APOA2 protein

NCBI chr13:83,644,460...83,646,358
Ensembl chr13:83,644,470...83,646,355

G

apolipoprotein B

increases expression

Atenolol results in increased expression of APOB; Atenolol results in increased expression of APOB protein

PMID:1928808 PMID:2193493

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

activating transcription factor 1

multiple interactions

Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein]

NCBI chr 7:131,361,962...131,404,677
Ensembl chr 7:131,362,450...131,404,670

G

beta-2 microglobulin

decreases expression

Atenolol results in decreased expression of B2M protein

NCBI chr 3:109,095,740...109,101,764
Ensembl chr 3:109,095,729...109,101,766

G

bradykinin receptor B2

affects response to substance

BDKRB2 exon polymorphism affects the susceptibility to Atenolol

NCBI chr 6:124,472,317...124,502,497
Ensembl chr 6:124,472,566...124,502,497

G

calcium voltage-gated channel subunit alpha1 C

increases response to substance

CACNA1C gene polymorphism results in increased susceptibility to Atenolol

NCBI chr 4:151,764,138...152,379,454
Ensembl chr 4:151,764,138...152,379,648

G

caspase 3

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]; Atenolol promotes the reaction [Quercetin inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]; Atenolol promotes the reaction [Thyroxine results in decreased expression of CAT protein]; Quercetin promotes the reaction [Atenolol inhibits the reaction [Isoproterenol results in decreased activity of CAT protein]]

PMID:2575990 PMID:22391854

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cyclin-dependent kinase 1

multiple interactions

Atenolol inhibits the reaction [Isoproterenol results in increased expression of CDK1 mRNA]

NCBI chr20:19,266,226...19,281,417
Ensembl chr20:19,266,248...19,281,408

G

cAMP responsive element binding protein 1

multiple interactions

Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

endothelin 1

affects response to substance

EDN1 gene polymorphism affects the susceptibility to Atenolol

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor receptor

multiple interactions

Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of EGFR protein]

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

Fas cell surface death receptor

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

FKBP prolyl isomerase 1B

multiple interactions

Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein]

NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653

G

FKBP prolyl isomerase 5

decreases expression

Atenolol results in decreased expression of FKBP5 mRNA

NCBI chr20:6,457,207...6,575,404
Ensembl chr20:6,457,216...6,541,674

G

glucose-6-phosphate dehydrogenase

multiple interactions

Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]; Atenolol inhibits the reaction [Isoproterenol results in increased activity of G6PD protein]

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

gap junction protein, alpha 1

increases expression

Atenolol results in increased expression of GJA1 protein

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, alpha 4

increases expression

Atenolol results in increased expression of GJA4 protein

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

G protein-coupled receptor kinase 2

decreases expression

Atenolol results in decreased expression of GRK2 mRNA; Atenolol results in decreased expression of GRK2 protein

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

insulin 2

multiple interactions

Atenolol inhibits the reaction [Terbutaline results in increased expression of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium inwardly-rectifying channel, subfamily J, member 2

affects response to substance

KCNJ2 gene affects the susceptibility to Atenolol

NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,060,821...96,071,445

G

potassium voltage-gated channel subfamily Q member 1

affects response to substance

KCNQ1 gene affects the susceptibility to Atenolol

NCBI chr 1:198,291,711...198,624,683
Ensembl chr 1:198,291,766...198,624,669

G

lipase C, hepatic type

multiple interactions

LIPC gene SNP affects the susceptibility to and affects the metabolism of Atenolol

NCBI chr 8:71,509,633...71,635,663
Ensembl chr 8:71,509,635...71,635,464

G

mitogen activated protein kinase 1

multiple interactions

[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK1 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]

PMID:16671086 PMID:17003101 PMID:17925438

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

[Atenolol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased phosphorylation of MAPK3 protein]; Atenolol inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]

PMID:16671086 PMID:17003101 PMID:17925438

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

nitric oxide synthase 2

multiple interactions

Atenolol inhibits the reaction [Carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

natriuretic peptide A

decreases expression

Atenolol results in decreased expression of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

multiple interactions
decreases expression
increases expression

[Atenolol co-treated with Doxazosin] results in decreased expression of NPPB mRNA; [Atenolol co-treated with Losartan co-treated with Doxazosin] results in decreased expression of NPPB mRNA
Atenolol results in decreased expression of NPPB mRNA
Atenolol results in increased expression of NPPB protein

PMID:15969258 PMID:18192850

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

phospholipase A2 group IVC

multiple interactions

PLA2G4C gene SNP affects the susceptibility to and affects the metabolism of Atenolol

NCBI chr 1:74,237,714...74,275,757
Ensembl chr 1:74,236,211...74,274,656

G

prostaglandin-endoperoxide synthase 2

multiple interactions

[Atenolol binds to and results in decreased activity of ADRB1 protein] inhibits the reaction [Nicotine results in increased expression of PTGS2 protein]

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

protein tyrosine phosphatase, non-receptor type 5

multiple interactions

Atenolol inhibits the reaction [Isoproterenol results in increased expression of PTPN5 protein]

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:97,620,642...97,679,882

G

renin

multiple interactions
decreases expression
decreases activity

[aliskiren co-treated with Atenolol] results in decreased activity of REN protein; [Dexamethasone co-treated with Nifedipine co-treated with Atenolol co-treated with Antihypertensive Agents] results in increased secretion of REN protein
Atenolol results in decreased expression of REN protein
Atenolol inhibits the reaction [2-(4-(2-carboxyethyl)phenethylamino)-5'-N-ethylcarboxamidoadenosine results in increased expression of REN protein]; Atenolol inhibits the reaction [2-hexynyladenosine-5'-N-ethylcarboxamide results in increased expression of REN protein]
Atenolol results in decreased activity of REN protein

PMID:3142437 PMID:3333524 PMID:9300315 PMID:14639093 PMID:18957387

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

ryanodine receptor 2

increases activity
multiple interactions

Atenolol results in increased activity of RYR2 protein
Atenolol promotes the reaction [FKBP1B protein binds to RYR2 protein]

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

solute carrier family 19 member 1

decreases expression

Atenolol results in decreased expression of SLC19A1 mRNA

NCBI chr20:11,584,410...11,602,429
Ensembl chr20:11,584,411...11,601,972

G

solute carrier family 22 member 1

multiple interactions

Atenolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 6 member 8

decreases expression

Atenolol results in decreased expression of SLC6A8 mRNA

NCBI chr X:151,384,675...151,393,979
Ensembl chr X:151,384,675...151,393,979

G

solute carrier organic anion transporter family, member 4C1

increases expression

Atenolol results in increased expression of SLCO4C1 mRNA

NCBI chr 9:97,177,497...97,229,161
Ensembl chr 9:97,178,861...97,229,715

G

small nucleolar RNA, H/ACA box 49

increases expression

Atenolol results in increased expression of SNORA49 mRNA

NCBI chr12:45,970,884...45,971,016
Ensembl chr12:45,970,884...45,971,016

G

small nuclear ribonucleoprotein polypeptide N

increases expression

Atenolol results in increased expression of SNRPN mRNA

NCBI chr 1:111,101,327...111,123,400
Ensembl chr 1:111,101,329...111,123,634

G

superoxide dismutase 1

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]
Atenolol promotes the reaction [Thyroxine results in decreased expression of SOD1 protein]

PMID:2575990 PMID:11163531

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]
Atenolol inhibits the reaction [Thyroxine results in increased expression of SOD2 protein]

PMID:2575990 PMID:11163531

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transient receptor potential cation channel, subfamily A, member 1

decreases response to substance

TRPA1 gene mutant form results in decreased susceptibility to Atenolol

NCBI chr 5:4,379,862...4,434,133
Ensembl chr 5:4,379,999...4,433,570

G

thioredoxin 1

increases expression

Atenolol results in increased expression of TXN mRNA

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

bambuterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acetylcholinesterase

decreases activity

bambuterol results in decreased activity of ACHE protein

NCBI chr12:19,406,133...19,413,713
Ensembl chr12:19,407,360...19,413,651

G

adrenoceptor beta 2

increases activity

bambuterol results in increased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

butyrylcholinesterase

decreases activity

bambuterol results in decreased activity of BCHE protein

PMID:15652380 PMID:18582854 PMID:18977317

NCBI chr 2:158,308,674...158,401,148
Ensembl chr 2:158,307,584...158,401,148

betaxolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions
affects binding

Betaxolol affects the reaction [Cocaine affects the expression of ADRB1 protein]; Betaxolol inhibits the reaction [Cocaine affects the expression of ADRB1 protein]
Betaxolol binds to ADRB1 protein
Betaxolol binds to and results in decreased activity of ADRB1 protein

PMID:10372227 PMID:11436944 PMID:17513029 PMID:18596687

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

[Betaxolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; Betaxolol binds to and results in decreased activity of ADRB2 protein

PMID:11436944 PMID:17925438

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

cAMP responsive element binding protein 1

multiple interactions

Betaxolol affects the reaction [Cocaine affects the phosphorylation of CREB1 protein]

NCBI chr 9:65,903,511...65,972,562
Ensembl chr 9:65,903,547...65,970,816

G

corticotropin releasing hormone

multiple interactions

Betaxolol affects the reaction [Cocaine affects the expression of CRH mRNA]

NCBI chr 2:102,143,055...102,144,919
Ensembl chr 2:102,143,055...102,144,919

G

natriuretic peptide A

decreases expression

Betaxolol results in decreased expression of NPPA mRNA; Betaxolol results in decreased expression of NPPA protein

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

decreases expression

Betaxolol results in decreased expression of NPPB mRNA

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

bevantolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

decreases expression

bevantolol results in decreased expression of ADRB1 mRNA

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

bisoprolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

increases transport
multiple interactions

ABCB1 protein results in increased transport of Bisoprolol
Bisoprolol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of Bisoprolol]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

adrenoceptor beta 1

decreases activity
increases expression
multiple interactions
affects binding

Bisoprolol results in decreased activity of ADRB1 protein
Bisoprolol results in increased expression of ADRB1 mRNA
[Bisoprolol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; Bisoprolol binds to and results in decreased activity of ADRB1 protein; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB1 protein]
Bisoprolol binds to ADRB1 protein

PMID:1389726 PMID:2897299 PMID:10372227 PMID:11562432 PMID:12535855 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
increases expression

[Bisoprolol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [Bisoprolol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; Bisoprolol binds to and results in decreased activity of ADRB2 protein; Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB2 protein]
Bisoprolol results in increased expression of ADRB2 mRNA

PMID:14730417 PMID:17925438 PMID:20668454

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Bisoprolol inhibits the reaction [cyanopindolol binds to ADRB3 protein]

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

C-C motif chemokine ligand 2

decreases expression

Bisoprolol results in decreased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

GNAS complex locus

increases expression

Bisoprolol results in increased expression of GNAS mRNA

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

interleukin 10

increases expression

Bisoprolol results in increased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 beta

decreases expression

Bisoprolol results in decreased expression of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression

Bisoprolol results in decreased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

multiple interactions

Bisoprolol inhibits the reaction [Terbutaline results in increased expression of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

protein kinase C, alpha

decreases expression

Bisoprolol results in decreased expression of PRKCA protein

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

decreases expression

Bisoprolol results in decreased expression of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

solute carrier family 22 member 1

multiple interactions

Bisoprolol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

multiple interactions

Bisoprolol inhibits the reaction [SLC22A2 protein results in increased uptake of Metformin]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

tumor necrosis factor

decreases expression

Bisoprolol results in decreased expression of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

bitolterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

multiple interactions
increases activity

ICI 118551 inhibits the reaction [bitolterol results in increased activity of ADRB2 protein]

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

bopindolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

decreases activity

bopindolol results in decreased activity of KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

solute carrier family 22 member 2

multiple interactions

bopindolol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

carteolol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions

Carteolol binds to and results in decreased activity of ADRB1 protein

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions

Carteolol binds to and results in decreased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

arrestin, beta 1

increases expression

Carteolol results in increased expression of ARRB1 protein

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

increases expression

Carteolol results in increased expression of ARRB2 protein

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

ATM serine/threonine kinase

multiple interactions
increases expression

Carteolol results in increased expression of and results in increased phosphorylation of ATM protein
Carteolol results in increased expression of ATM mRNA

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

catalase

affects activity

Carteolol affects the activity of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 27

increases expression

Carteolol results in increased expression of CCL27 mRNA

NCBI chr 5:56,941,402...56,948,511
Ensembl chr 5:56,941,402...56,948,506

G

cyclin-dependent kinase inhibitor 1A

affects expression

Carteolol affects the expression of CDKN1A mRNA

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2A

increases expression

Carteolol results in increased expression of CDKN2A mRNA

NCBI chr 5:103,984,949...103,992,143
Ensembl chr 5:103,984,949...104,003,149

G

fumarylacetoacetate hydrolase domain containing 1

affects expression

Carteolol affects the expression of FAHD1 mRNA

NCBI chr10:13,873,539...13,874,978
Ensembl chr10:13,873,527...13,875,012

G

glutathione peroxidase 1

affects activity

Carteolol affects the activity of GPX1 protein

NCBI chr 8:109,026,905...109,028,031
Ensembl chr 8:109,026,905...109,028,024

G

H2A.X variant histone

increases phosphorylation

Carteolol results in increased phosphorylation of H2AX protein

NCBI chr 8:44,671,907...44,673,262
Ensembl chr 8:44,671,786...44,673,239
Ensembl chr 4:44,671,786...44,673,239

G

hexokinase 2

affects expression

Carteolol affects the expression of HK2 mRNA

NCBI chr 4:115,234,509...115,283,530
Ensembl chr 4:115,234,509...115,283,530

G

interleukin 10

increases expression

Carteolol results in increased expression of IL10 mRNA

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 1 alpha

increases expression

Carteolol results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 6

increases expression

Carteolol results in increased expression of IL6 mRNA

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lamin B1

decreases expression

Carteolol results in decreased expression of LMNB1 protein

NCBI chr18:50,175,861...50,215,210
Ensembl chr18:50,175,874...50,214,502

G

microtubule-associated protein 1 light chain 3 beta

affects localization

Carteolol affects the localization of MAP1LC3B protein

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen activated protein kinase 1

multiple interactions

Carteolol results in increased expression of and results in increased phosphorylation of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Carteolol results in increased expression of and results in increased phosphorylation of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

marker of proliferation Ki-67

decreases expression

Carteolol results in decreased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

mechanistic target of rapamycin kinase

affects expression

Carteolol affects the expression of MTOR protein

NCBI chr 5:158,884,856...158,994,311
Ensembl chr 5:158,884,804...158,994,311

G

nicotinamide phosphoribosyltransferase

affects expression

Carteolol affects the expression of NAMPT mRNA

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

NFE2 like bZIP transcription factor 2

affects expression

Carteolol affects the expression of NFE2L2 mRNA

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

increases expression

Carteolol results in increased expression of NFKB1 mRNA

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NADPH oxidase 4

increases expression

Carteolol results in increased expression of NOX4 protein

NCBI chr 1:140,900,886...141,078,844
Ensembl chr 1:140,901,097...141,077,406

G

poly (ADP-ribose) polymerase 1

affects expression

Carteolol affects the expression of PARP1 mRNA

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

G

sirtuin 1

affects expression

Carteolol affects the expression of SIRT1 mRNA

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

superoxide dismutase 1

affects activity

Carteolol affects the activity of SOD1 protein

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

affects activity

Carteolol affects the activity of SOD2 protein

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

transforming growth factor, beta 1

increases expression

Carteolol results in increased expression of TGFB1 mRNA

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

increases expression

Carteolol results in increased expression of TNF mRNA

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

affects expression

Carteolol affects the expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

carvedilol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases expression

Carvedilol inhibits the reaction [Albuterol results in increased expression of ABCB11 mRNA]
Carvedilol results in decreased expression of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases transport
multiple interactions
decreases activity

ABCB1 protein results in increased transport of carvedilol
[Cyclosporine results in decreased activity of ABCB1 protein] which results in increased uptake of carvedilol
[carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]] which results in decreased susceptibility to Daunorubicin; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Doxorubicin]] which results in decreased susceptibility to Doxorubicin; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]] which results in decreased susceptibility to Paclitaxel; [carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]] which results in decreased susceptibility to Vinblastine; [carvedilol results in decreased activity of ABCB1 protein] which results in increased susceptibility to Doxorubicin; [carvedilol results in decreased activity of ABCB1 protein] which results in increased uptake of fluorexon; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Daunorubicin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Digoxin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Doxorubicin]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Paclitaxel]; carvedilol inhibits the reaction [ABCB1 protein results in increased transport of Vinblastine]; valspodar inhibits the reaction [ABCB1 protein results in increased transport of carvedilol]

PMID:10571255 PMID:11895100 PMID:12708479 PMID:16671962 PMID:17609666

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily C member 2

decreases expression

Carvedilol results in decreased expression of ABCC2 protein

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 4

decreases expression

Carvedilol results in decreased expression of ABCC4 protein

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

angiotensin I converting enzyme

multiple interactions

carvedilol inhibits the reaction [Colchicine results in decreased activity of ACE protein]
carvedilol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of ACE mRNA]

PMID:15071347 PMID:18992766

NCBI chr10:90,910,316...90,930,437
Ensembl chr10:90,910,316...90,931,131

G

actin alpha 2, smooth muscle

multiple interactions
decreases expression

Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of ACTA2 protein]; Carvedilol inhibits the reaction [Ethanol results in increased expression of ACTA2 mRNA]; Carvedilol inhibits the reaction [Ethanol results in increased expression of ACTA2 protein]
carvedilol results in decreased expression of ACTA2 protein

PMID:20403466 PMID:22413959 PMID:30254303

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

actinin alpha 4

decreases expression

carvedilol results in decreased expression of ACTN4 protein

NCBI chr 1:84,182,783...84,251,867
Ensembl chr 1:84,182,788...84,251,847

G

adiponectin, C1Q and collagen domain containing

decreases expression

carvedilol results in decreased expression of ADIPOQ protein

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adrenoceptor alpha 1A

multiple interactions
decreases expression

Carvedilol binds to and results in decreased activity of ADRA1A protein; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]
carvedilol results in decreased expression of ADRA1A mRNA

PMID:15306222 PMID:20668454

NCBI chr15:40,830,125...40,935,902
Ensembl chr15:40,832,534...40,927,500

G

adrenoceptor alpha 1B

multiple interactions

carvedilol binds to and results in decreased activity of ADRA1B protein; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]

NCBI chr10:28,255,025...28,373,418
Ensembl chr10:28,255,025...28,312,919

G

adrenoceptor alpha 1D

multiple interactions

carvedilol binds to and results in decreased activity of ADRA1D protein; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein]; carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein]; carvedilol inhibits the reaction [[Phenylephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]

NCBI chr 3:118,793,356...118,809,354
Ensembl chr 3:118,793,346...118,809,354

G

adrenoceptor beta 1

multiple interactions
affects binding
increases expression
increases phosphorylation
increases activity
affects response to substance

[ADRB1 gene co-treated with ADRB2 gene] affects the susceptibility to Carvedilol; [Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP; ADRB1 protein polymorphism affects the reaction [[Carvedilol binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP]; ADRB1 protein polymorphism affects the susceptibility to [Carvedilol co-treated with Angiotensin Receptor Antagonists]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Carvedilol binds to and results in decreased activity of ADRB1 protein; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Carvedilol inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; Carvedilol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; CGP 20712A inhibits the reaction [[Carvedilol co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [Carvedilol results in increased activity of ADRB1 protein]; Guanine Nucleotides affects the reaction [Carvedilol binds to ADRB1 protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
carvedilol binds to ADRB1 protein
carvedilol results in increased expression of ADRB1 mRNA
carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; carvedilol inhibits the reaction [Dihydroalprenolol binds to ADRB1 protein]
[carvedilol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein; carvedilol results in increased phosphorylation of ADRB1 protein
carvedilol results in increased activity of ADRB1 protein
ADRB1 gene polymorphism affects the susceptibility to carvedilol; ADRB1 protein polymorphism affects the susceptibility to carvedilol

PMID:1378154 PMID:2462161 PMID:7908256 PMID:10372227 PMID:12535855 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
increases phosphorylation
affects binding
increases expression
increases uptake
affects response to substance

[ADRB1 gene co-treated with ADRB2 gene] affects the susceptibility to carvedilol; [carvedilol binds to ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; [carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; [carvedilol binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; [carvedilol co-treated with ADRB2 protein] results in increased expression of GNAS protein; [carvedilol co-treated with ADRB2 protein] results in increased expression of GRK2 protein; carvedilol binds to and results in decreased activity of ADRB2 protein; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [cyanopindolol binds to ADRB2 protein]; carvedilol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]; Guanine Nucleotides affects the reaction [carvedilol binds to ADRB2 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; ICI 118551 inhibits the reaction [[carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol results in increased phosphorylation of ADRB2 protein]
carvedilol results in increased expression of ADRB2 mRNA
carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [Dihydroalprenolol binds to ADRB2 protein]
carvedilol inhibits the reaction [ADRB2 results in decreased susceptibility to Histamine]; carvedilol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein]
carvedilol results in increased uptake of ADRB2 protein
ADRB2 gene SNP affects the susceptibility to carvedilol; ADRB2 protein polymorphism affects the susceptibility to carvedilol

PMID:1378154 PMID:2462161 PMID:10372227 PMID:10455254 PMID:12198331 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions
decreases expression
affects response to substance

carvedilol inhibits the reaction [cyanopindolol binds to ADRB3 protein]
carvedilol results in decreased expression of ADRB3 mRNA
ADRB3 affects the susceptibility to carvedilol

PMID:11159692 PMID:14730417 PMID:17440824

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

angiotensinogen

multiple interactions
decreases response to substance
decreases expression

[Losartan co-treated with Carvedilol] results in decreased susceptibility to AGT protein modified form; Carvedilol inhibits the reaction [AGT protein affects the localization of RAC1 protein]; Carvedilol inhibits the reaction [AGT protein results in increased abundance of Glycerol]; Carvedilol inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Carvedilol inhibits the reaction [AGT protein results in increased abundance of Reactive Oxygen Species]; Carvedilol inhibits the reaction [Losartan results in decreased susceptibility to AGT protein modified form]; Losartan inhibits the reaction [Carvedilol results in decreased susceptibility to AGT protein modified form]
carvedilol results in decreased susceptibility to AGT protein modified form
carvedilol inhibits the reaction [AGT protein modified form promotes the reaction [Phenylephrine results in increased abundance of Inositol Phosphates]]; carvedilol inhibits the reaction [AGT protein modified form results in increased susceptibility to Phenylephrine]
carvedilol results in decreased expression of AGT protein

PMID:12004934 PMID:12538430 PMID:15741261 PMID:16794485 PMID:16940222 More...

NCBI chr19:52,529,139...52,549,618
Ensembl chr19:52,529,185...52,540,977

G

AKT serine/threonine kinase 1

increases phosphorylation

carvedilol results in increased phosphorylation of AKT1 protein

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

amyloid beta precursor protein

decreases expression

carvedilol results in decreased expression of APP protein modified form

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

arrestin, beta 1

multiple interactions

[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA; [carvedilol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA; ARRB1 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; carvedilol promotes the reaction [ADRB1 protein binds to ARRB1 protein]; carvedilol promotes the reaction [ARRB1 protein binds to DROSHA protein]; carvedilol promotes the reaction [ARRB1 protein binds to HNRNPA1 protein]; Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK5 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK6 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]
ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125A mRNA]; ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR150 mRNA]; ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR214 mRNA]; carvedilol promotes the reaction [ARRB1 protein binds to DROSHA protein]; carvedilol promotes the reaction [ARRB1 protein binds to HNRNPA1 protein]

PMID:18787115 PMID:24334028

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions
affects localization

ARRB2 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]; ARRB2 protein promotes the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]; carvedilol promotes the reaction [ADRB1 protein binds to ARRB2 protein]; carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]; ICI 118551 inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]; Propranolol inhibits the reaction [carvedilol promotes the reaction [ADRB2 protein binds to ARRB2 protein]]
ARRB2 promotes the reaction [carvedilol results in increased uptake of Calcium]
carvedilol affects the localization of ARRB2 protein

PMID:17925438 PMID:18787115 PMID:21078978

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2

multiple interactions
increases expression

carvedilol inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP2A2 mRNA]; carvedilol inhibits the reaction [Hydrogen Peroxide results in decreased expression of ATP2A2 protein]
carvedilol results in increased expression of ATP2A2 mRNA

PMID:15670758 PMID:16026515 PMID:16162791

NCBI chr12:34,072,710...34,122,142
Ensembl chr12:34,072,683...34,122,101

G

arginine vasopressin

decreases expression
multiple interactions

carvedilol results in decreased expression of AVP protein
carvedilol inhibits the reaction [AVP protein results in increased import of and results in increased abundance of Calcium]

PMID:12523682 PMID:14711191

NCBI chr 3:117,793,447...117,805,091
Ensembl chr 3:117,793,457...117,795,425

G

BCL2-antagonist/killer 1

multiple interactions

[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of BAK1 mRNA

NCBI chr20:5,100,480...5,109,669
Ensembl chr20:5,100,480...5,109,264

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression
decreases expression

carvedilol inhibits the reaction [Doxorubicin results in increased expression of BAX mRNA]; carvedilol inhibits the reaction [Doxorubicin results in increased expression of BAX protein]; carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of BAX protein]
carvedilol inhibits the reaction [Cisplatin results in increased expression of BAX protein]
carvedilol results in increased expression of BAX protein
carvedilol results in decreased expression of BAX

PMID:12973927 PMID:15380674 PMID:20079142 PMID:24012798 PMID:25245570 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions
increases expression
affects expression

carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 mRNA]; carvedilol inhibits the reaction [Doxorubicin results in decreased expression of BCL2 protein]; carvedilol inhibits the reaction [Potassium Dichromate results in decreased expression of BCL2 protein]
carvedilol results in increased expression of BCL2 mRNA
carvedilol affects the expression of BCL2 protein

PMID:15380674 PMID:16780994 PMID:16909474 PMID:22000973 PMID:25245570 More...

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

increases expression

carvedilol results in increased expression of BCL2L1 protein

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

beclin 1

increases expression

carvedilol results in increased expression of BECN1 protein

NCBI chr10:86,231,387...86,246,742
Ensembl chr10:86,231,388...86,246,742

G

calcitonin-related polypeptide alpha

multiple interactions

capsazepine inhibits the reaction [carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein]]; carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein]

NCBI chr 1:168,878,212...168,883,176
Ensembl chr 1:168,878,214...168,883,105

G

calcitonin-related polypeptide, beta

multiple interactions

capsazepine inhibits the reaction [carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein]]; carvedilol results in increased secretion of [CALCA protein co-treated with CALCB protein]

NCBI chr 1:168,965,383...168,970,259
Ensembl chr 1:168,966,465...168,970,125

G

calcium/calmodulin-dependent protein kinase II delta

multiple interactions

[Carvedilol co-treated with aliskiren] inhibits the reaction [Isoproterenol results in increased expression of CAMK2D protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of CAMK2D protein]

NCBI chr 2:215,023,785...215,287,351
Ensembl chr 2:215,024,004...215,286,178

G

caspase 3

multiple interactions

[Carvedilol co-treated with aliskiren] inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]; Carvedilol inhibits the reaction [Cisplatin results in increased activity of CASP3 protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased activity of CASP3 protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of CASP3 protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of CASP3 protein]; Carvedilol inhibits the reaction [Potassium Dichromate results in increased cleavage of CASP3 protein]
carvedilol inhibits the reaction [Cisplatin results in increased cleavage of and results in increased activity of CASP3 protein]
carvedilol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]

PMID:10728402 PMID:15380674 PMID:21044617 PMID:24012798 PMID:25245570 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions
increases activity

Carvedilol inhibits the reaction [Arginine results in decreased activity of CAT protein]; Carvedilol inhibits the reaction [Chlorpromazine results in decreased expression of CAT protein]; Carvedilol inhibits the reaction [Haloperidol results in decreased expression of CAT protein]; Carvedilol inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of CAT protein]; Carvedilol inhibits the reaction [Potassium Dichromate results in decreased activity of CAT protein]
carvedilol results in increased activity of CAT protein

PMID:12010767 PMID:16909474 PMID:25245570 PMID:25496245 PMID:32569593

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cadherin 1

multiple interactions

Carvedilol inhibits the reaction [Carbon Tetrachloride results in decreased expression of CDH1 protein]

NCBI chr19:34,492,371...34,561,775
Ensembl chr19:34,492,371...34,561,775

G

cofilin 1

decreases expression

carvedilol results in decreased expression of CFL1 protein

NCBI chr 1:202,796,012...202,801,337
Ensembl chr 1:202,786,627...202,817,587

G

creatine kinase B

multiple interactions

Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of [CKM protein binds to CKB protein]]

NCBI chr 6:130,729,420...130,732,301
Ensembl chr 6:130,729,423...130,732,315

G

creatine kinase, M-type

multiple interactions

[Carvedilol co-treated with aliskiren] inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of CKM protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of [CKM protein binds to CKB protein]]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of CKM protein]

PMID:25496245 PMID:26982530

NCBI chr 1:79,061,390...79,071,721
Ensembl chr 1:79,061,456...79,071,720

G

collagen type I alpha 1 chain

multiple interactions
decreases expression

carvedilol inhibits the reaction [[Sodium, Dietary co-treated with Dietary Fats] results in increased expression of COL1A1 mRNA]; carvedilol inhibits the reaction [Ethanol results in increased expression of COL1A1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]
carvedilol decreases expression of collagen I mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats
Carvedilol results in decreased expression of COL1A1 mRNA; Carvedilol results in decreased expression of COL1A1 protein

CTD
RGD

PMID:10722803 PMID:11181017 PMID:11682445 PMID:19575289 PMID:21216836 More...

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

collagen type III alpha 1 chain

multiple interactions
decreases expression

carvedilol inhibits the reaction [[Sodium, Dietary co-treated with Dietary Fats] results in increased expression of COL3A1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]
carvedilol decreases expression of collagen III mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats
carvedilol results in decreased expression of COL3A1 protein

CTD
RGD

PMID:10722803 PMID:11181017 PMID:11682445 PMID:11682445

NCBI chr 9:47,374,611...47,410,547
Ensembl chr 9:47,374,593...47,410,547

G

C-reactive protein

decreases expression
multiple interactions

carvedilol results in decreased expression of CRP protein
Carvedilol inhibits the reaction [Arginine results in increased expression of CRP protein]

PMID:15047035 PMID:32569593

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

colony stimulating factor 2

multiple interactions

carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 mRNA]; carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 protein]

NCBI chr10:38,386,945...38,388,926
Ensembl chr10:38,386,945...38,389,199

G

cytochrome c, somatic

increases expression

carvedilol results in increased expression of CYCS protein

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

cytochrome P450, family 1, subfamily a, polypeptide 1

decreases activity

Carvedilol results in decreased activity of CYP1A1 protein

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily b, polypeptide 1

decreases activity

Carvedilol results in decreased activity of CYP1B1 protein

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, subfamily 2, polypeptide 11

increases metabolic processing

CYP2C11 protein results in increased metabolism of carvedilol

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily d, polypeptide 2

increases metabolic processing

CYP2D2 protein results in increased metabolism of carvedilol

NCBI chr 7:113,935,138...113,939,209
Ensembl chr 7:113,935,138...113,939,209

G

cytochrome P450, family 2, subfamily d, polypeptide 4

affects glucuronidation
affects metabolic processing
affects response to substance

CYP2D6 gene polymorphism affects the glucuronidation of carvedilol
CYP2D6 gene polymorphism affects the metabolism of carvedilol; CYP2D6 protein polymorphism affects the metabolism of carvedilol
CYP2D6 gene polymorphism affects the susceptibility to carvedilol

PMID:15001973 PMID:16595916 PMID:16849011 PMID:17329852 PMID:20643254 More...

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases metabolic processing

CYP3A2 protein results in increased metabolism of carvedilol

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases metabolic processing

CYP3A23-3A1 protein results in increased metabolism of Carvedilol

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450 family 7 subfamily A member 1

increases expression

Carvedilol results in increased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DNA-damage-inducible transcript 4

decreases expression

carvedilol results in decreased expression of DDIT4 mRNA

NCBI chr20:27,891,989...27,894,088
Ensembl chr20:27,891,998...27,894,105

G

drosha ribonuclease III

multiple interactions

carvedilol promotes the reaction [ARRB1 protein binds to DROSHA protein]

NCBI chr 2:61,864,886...61,976,688
Ensembl chr 2:61,864,970...61,976,688

G

endothelin 1

decreases secretion
decreases expression
multiple interactions

carvedilol results in decreased secretion of EDN1 protein
carvedilol results in decreased expression of EDN1 mRNA
carvedilol inhibits the reaction [EDN1 protein results in increased import of and results in increased abundance of Calcium]
carvedilol results in decreased expression of EDN1 mRNA; carvedilol results in decreased expression of EDN1 protein
carvedilol inhibits the reaction [Glucose results in increased expression of EDN1 mRNA]; carvedilol inhibits the reaction [Glucose results in increased expression of EDN1 protein]

PMID:9500873 PMID:11078433 PMID:14711191 PMID:16428915 PMID:18971572

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

epidermal growth factor receptor

multiple interactions
increases phosphorylation

AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
[carvedilol results in increased phosphorylation of ADRB1 protein] which results in increased phosphorylation of EGFR protein

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

coagulation factor III, tissue factor

multiple interactions

[irbesartan co-treated with carvedilol] results in decreased expression of F3 mRNA; [irbesartan co-treated with carvedilol] results in decreased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

Fas cell surface death receptor

multiple interactions

carvedilol inhibits the reaction [Epinephrine results in increased expression of FAS protein]

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions

carvedilol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

multiple interactions

carvedilol inhibits the reaction [Ethanol results in increased expression of FASN mRNA]

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

FKBP prolyl isomerase 1B

multiple interactions

carvedilol promotes the reaction [FKBP1B protein binds to RYR2 protein]

NCBI chr 6:27,832,128...27,850,600
Ensembl chr 6:27,838,802...27,848,653

G

fibronectin 1

multiple interactions
decreases expression

carvedilol inhibits the reaction [[Sodium, Dietary co-treated with Dietary Fats] results in increased expression of FN1 mRNA]; carvedilol inhibits the reaction [Streptozocin results in increased expression of FN1 protein]
carvedilol decreases expression of fibronectin mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats
carvedilol results in decreased expression of FN1 protein

CTD
RGD

PMID:11181017 PMID:11682445 PMID:12140129 PMID:11682445

NCBI chr 9:73,196,044...73,264,695
Ensembl chr 9:73,196,044...73,264,678

G

growth associated protein 43

decreases expression

carvedilol results in decreased expression of GAP43 mRNA; carvedilol results in decreased expression of GAP43 protein

NCBI chr11:58,376,371...58,470,047
Ensembl chr11:58,376,371...58,470,045

G

GATA binding protein 4

decreases phosphorylation

carvedilol results in decreased phosphorylation of GATA4 protein

NCBI chr15:37,459,601...37,531,291
Ensembl chr15:37,459,601...37,505,636

G

gap junction protein, alpha 1

increases expression
affects localization
decreases phosphorylation
increases phosphorylation
decreases degradation

carvedilol results in increased expression of GJA1 mRNA; carvedilol results in increased expression of GJA1 protein
carvedilol affects the localization of GJA1 protein
carvedilol results in decreased phosphorylation of GJA1 protein
carvedilol results in increased phosphorylation of GJA1 protein
carvedilol results in decreased degradation of GJA1 protein

PMID:16448880 PMID:16563290 PMID:17445419 PMID:18971572 PMID:19478468

NCBI chr20:35,756,007...35,768,481
Ensembl chr20:35,755,991...35,768,582

G

gap junction protein, alpha 4

increases expression

carvedilol results in increased expression of GJA4 protein

NCBI chr 5:139,633,324...139,635,857
Ensembl chr 5:139,633,287...139,635,925

G

GNAS complex locus

multiple interactions
increases expression

[carvedilol co-treated with ADRB2 protein] results in increased expression of GNAS protein
carvedilol results in increased expression of GNAS mRNA

PMID:10455254 PMID:20668454

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

glutamic-oxaloacetic transaminase 1

multiple interactions

Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GOT1 protein]

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glycoprotein nmb

decreases expression

carvedilol results in decreased expression of GPNMB protein

NCBI chr 4:78,010,247...78,031,491
Ensembl chr 4:78,010,197...78,049,367

G

glutamic--pyruvic transaminase

multiple interactions

Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of GPT protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased expression of and results in increased secretion of GPT protein]

PMID:25496245 PMID:30254303

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

G protein-coupled receptor kinase 2

multiple interactions
decreases expression
increases expression

[carvedilol co-treated with ADRB2 protein] results in increased expression of GRK2 protein
carvedilol results in decreased expression of GRK2 protein
carvedilol results in increased expression of GRK2 protein
carvedilol inhibits the reaction [ADRB2 results in increased expression of GRK2 protein]

PMID:9788834 PMID:10455254 PMID:12198331

NCBI chr 1:201,580,823...201,601,580
Ensembl chr 1:201,581,480...201,601,582

G

G protein-coupled receptor kinase 5

multiple interactions

GRK5 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]
GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125A mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR150 mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR214 mRNA]

NCBI chr 1:260,028,269...260,223,699
Ensembl chr 1:260,028,242...260,218,701

G

G protein-coupled receptor kinase 6

multiple interactions

GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125B-1 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA]
GRK6 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,177,019...9,192,644

G

heparin-binding EGF-like growth factor

multiple interactions

HBEGF protein inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

heme oxygenase 1

increases expression

carvedilol results in increased expression of HMOX1 mRNA

PMID:11688356 PMID:12227681

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heterogeneous nuclear ribonucleoprotein A1

multiple interactions

carvedilol promotes the reaction [ARRB1 protein binds to HNRNPA1 protein]

NCBI chr 7:134,375,318...134,381,610
Ensembl chr 7:134,375,150...134,381,609

G

hippocalcin

affects localization

carvedilol affects the localization of HPCA protein

NCBI chr 5:141,455,616...141,466,252
Ensembl chr 5:141,455,613...141,463,841

G

heat shock protein family H (Hsp110) member 1

increases expression

carvedilol results in increased expression of HSPH1 protein

NCBI chr12:5,390,916...5,410,224
Ensembl chr12:5,390,922...5,410,224

G

interferon gamma

multiple interactions

carvedilol inhibits the reaction [Hemagglutinins results in increased expression of IFNG protein]

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

inhibitor of nuclear factor kappa B kinase subunit beta

multiple interactions

carvedilol inhibits the reaction [Doxorubicin results in increased expression of IKBKB protein]

NCBI chr16:69,319,487...69,373,251
Ensembl chr16:69,319,554...69,373,250

G

interleukin 10

multiple interactions
increases expression

carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 mRNA]; carvedilol inhibits the reaction [CSF2 results in increased expression of IL10 protein]
carvedilol results in increased expression of IL10 mRNA; carvedilol results in increased expression of IL10 protein

PMID:12722941 PMID:16310260 PMID:18971572 PMID:20017808

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12A

multiple interactions

carvedilol promotes the reaction [Hemagglutinins results in increased expression of [IL12A protein binds to IL12B protein]]; carvedilol promotes the reaction [Lipopolysaccharides results in increased expression of [IL12A protein binds to IL12B protein]]

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

interleukin 12B

multiple interactions

carvedilol promotes the reaction [Hemagglutinins results in increased expression of [IL12A protein binds to IL12B protein]]; carvedilol promotes the reaction [Lipopolysaccharides results in increased expression of [IL12A protein binds to IL12B protein]]

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 beta

decreases expression
multiple interactions

carvedilol results in decreased expression of IL1B mRNA
carvedilol results in decreased expression of IL1B mRNA; carvedilol results in decreased expression of IL1B protein
Carvedilol inhibits the reaction [Arginine results in increased expression of IL1B protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL1B mRNA]
carvedilol inhibits the reaction [Lipopolysaccharides results in increased secretion of IL1B protein]

PMID:10722803 PMID:14684360 PMID:15921778 PMID:16310260 PMID:20017808 More...

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 1 receptor antagonist

increases expression

carvedilol results in increased expression of IL1RN protein

NCBI chr 3:7,111,567...7,127,451
Ensembl chr 3:7,111,550...7,127,445

G

interleukin 6

decreases expression
multiple interactions

carvedilol results in decreased expression of IL6 mRNA; carvedilol results in decreased expression of IL6 protein
carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]

PMID:10722803 PMID:11406463 PMID:16310260

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 2

decreases expression

carvedilol results in decreased expression of INS protein alternative form

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

junctophilin 2

increases expression

carvedilol results in increased expression of JPH2 protein

NCBI chr 3:151,994,768...152,058,941
Ensembl chr 3:151,994,778...152,058,904

G

potassium voltage-gated channel subfamily A member 5

multiple interactions

carvedilol binds to and results in decreased activity of KCNA5 protein

NCBI chr 4:159,354,689...159,358,173
Ensembl chr 4:159,350,097...159,357,697

G

potassium voltage-gated channel subfamily H member 2

decreases activity
affects activity

carvedilol results in decreased activity of KCNH2 protein
carvedilol affects the activity of KCNH2 protein

PMID:11164846 PMID:16314852 PMID:22020101

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

potassium inwardly-rectifying channel, subfamily J, member 11

decreases activity

carvedilol results in decreased activity of KCNJ11 protein

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

potassium inwardly-rectifying channel, subfamily J, member 4

multiple interactions

carvedilol binds to and results in decreased activity of KCNJ4 protein; Phosphatidylinositol Phosphates inhibits the reaction [carvedilol binds to and results in decreased activity of KCNJ4 protein]

NCBI chr 7:111,047,097...111,074,151
Ensembl chr 7:111,047,094...111,074,151

G

potassium two pore domain channel subfamily K member 3

decreases activity

carvedilol results in decreased activity of KCNK3 protein

NCBI chr 6:25,761,487...25,799,153
Ensembl chr 6:25,763,228...25,799,153

G

KLF transcription factor 13

multiple interactions

[[Oxygen deficiency co-treated with Glucose deficiency] results in increased susceptibility to Carvedilol] which results in decreased expression of KLF13 mRNA

NCBI chr 1:117,505,857...117,536,626
Ensembl chr 1:117,503,602...117,551,227

G

lysyl oxidase

decreases expression

carvedilol results in decreased expression of LOX mRNA

NCBI chr18:45,964,544...45,977,431
Ensembl chr18:45,967,343...46,041,477

G

mitogen activated protein kinase 1

multiple interactions
increases phosphorylation

[Doxorubicin co-treated with carvedilol] results in increased phosphorylation of MAPK1 protein; carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]
[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Carvedilol results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK1 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ICI 118551 inhibits the reaction [[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK1 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]

PMID:11054474 PMID:15306222 PMID:16213474 PMID:17925438 PMID:18787115

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 14

multiple interactions

carvedilol inhibits the reaction [Doxorubicin results in increased phosphorylation of MAPK14 protein]

NCBI chr20:6,749,646...6,810,590
Ensembl chr20:6,749,670...6,810,589

G

mitogen activated protein kinase 3

multiple interactions
increases phosphorylation

[Doxorubicin co-treated with carvedilol] results in increased phosphorylation of MAPK3 protein; carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein]
carvedilol results in increased phosphorylation of MAPK3 protein
Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]
[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB1 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Carvedilol results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1A protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1B protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [[Phenylephrine co-treated with ADRA1D protein] results in increased phosphorylation of MAPK3 protein]; Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ICI 118551 inhibits the reaction [[Carvedilol binds to ADRB2 protein] which results in increased phosphorylation of MAPK3 protein]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

PMID:11054474 PMID:15306222 PMID:16213474 PMID:17925438 PMID:18787115

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

milk fat globule EGF and factor V/VIII domain containing

decreases expression

carvedilol results in decreased expression of MFGE8 protein

NCBI chr 1:133,064,665...133,080,069
Ensembl chr 1:133,064,665...133,080,073

G

microRNA 125a

multiple interactions
increases expression

[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125A mRNA
ARRB1 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]; GRK5 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR125A mRNA]
carvedilol results in increased expression of MIR125A mRNA

NCBI chr 1:58,677,626...58,677,710
Ensembl chr 1:58,677,626...58,677,710

G

microRNA 125b-1

multiple interactions
increases expression

ARRB1 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; GRK5 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]; GRK6 gene mutant form inhibits the reaction [carvedilol results in increased expression of MIR125B-1 mRNA]
[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR125B-1 mRNA

NCBI chr 8:41,952,966...41,953,052
Ensembl chr 8:41,952,966...41,953,052

G

microRNA 125b-2

increases expression

Carvedilol results in increased expression of MIR125B2 mRNA

NCBI chr11:16,245,620...16,245,707

G

microRNA 150

multiple interactions
increases expression

[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR150 mRNA
ARRB1 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]; GRK5 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR150 mRNA]

NCBI chr 1:95,605,024...95,605,108
Ensembl chr 1:95,605,024...95,605,108

G

microRNA 190

multiple interactions

[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA; Colforsin inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK5 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; GRK6 mutant form inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]; Metoprolol inhibits the reaction [[carvedilol co-treated with ARRB1 protein] results in increased expression of MIR190A mRNA]

NCBI chr 8:67,850,987...67,851,071
Ensembl chr 8:67,850,987...67,851,071

G

microRNA 200a

multiple interactions

Carvedilol inhibits the reaction [Carbon Tetrachloride results in decreased expression of MIR200A mRNA]

NCBI chr 5:166,648,494...166,648,582

G

microRNA 214

multiple interactions
increases expression

ARRB1 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA]; GRK5 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA]; GRK6 gene mutant form inhibits the reaction [Carvedilol results in increased expression of MIR214 mRNA]
[Carvedilol co-treated with ARRB1 protein] results in increased expression of MIR214 mRNA

NCBI chr13:74,588,374...74,588,481
Ensembl chr13:74,588,372...74,588,481

G

matrix metallopeptidase 2

multiple interactions
decreases activity
decreases expression

carvedilol inhibits the reaction [Doxorubicin results in increased expression of MMP2 mRNA]
carvedilol results in decreased activity of MMP2 protein
carvedilol inhibits the reaction [TNF protein results in increased expression of MMP2 protein]
carvedilol results in decreased expression of MMP2

PMID:16213474 PMID:16310260 PMID:17964422 PMID:20452391

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 8

decreases expression

carvedilol results in decreased expression of MMP8 mRNA

NCBI chr 8:4,724,009...4,733,864
Ensembl chr 8:4,724,029...4,733,520

G

matrix metallopeptidase 9

affects activity
decreases expression
decreases activity
multiple interactions

carvedilol affects the activity of MMP9 protein
carvedilol results in decreased expression of MMP9 mRNA
carvedilol results in decreased activity of MMP9 protein
carvedilol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]
carvedilol inhibits the reaction [Doxorubicin results in increased expression of MMP9 mRNA]

PMID:16213474 PMID:16310260 PMID:16574429 PMID:17964422 PMID:18971572

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

G

myeloperoxidase

multiple interactions

carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased expression of MPO protein]
Carvedilol inhibits the reaction [Arginine results in increased expression of MPO protein]
carvedilol inhibits the reaction [Calcimycin results in increased secretion of MPO protein]; carvedilol inhibits the reaction [N-Formylmethionine Leucyl-Phenylalanine results in increased secretion of MPO protein]; carvedilol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of MPO protein]

PMID:16601795 PMID:17159805 PMID:18987595 PMID:32569593

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

moesin

decreases expression

carvedilol results in decreased expression of MSN protein

NCBI chr X:60,996,043...61,064,011
Ensembl chr X:60,995,951...61,065,628

G

myostatin

decreases expression

carvedilol results in decreased expression of MSTN mRNA; carvedilol results in decreased expression of MSTN protein

NCBI chr 9:48,452,533...48,458,933
Ensembl chr 9:48,452,533...48,458,933

G

MYC proto-oncogene, bHLH transcription factor

decreases expression
affects expression

carvedilol results in decreased expression of MYC protein
carvedilol affects the expression of MYC protein

PMID:21472269 PMID:22000973

NCBI chr 7:93,593,705...93,598,633
Ensembl chr 7:93,593,705...93,598,630

G

myosin light chain 12A

decreases expression

carvedilol results in decreased expression of MYL12A protein

NCBI chr 9:110,891,970...110,899,655
Ensembl chr 9:110,873,959...110,916,580

G

nuclear factor of activated T-cells 4

increases phosphorylation

carvedilol results in increased phosphorylation of NFATC4 protein

NCBI chr15:29,286,998...29,314,610
Ensembl chr15:29,305,535...29,314,610

G

nitric oxide synthase 2

multiple interactions

Atenolol inhibits the reaction [carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; carvedilol promotes the reaction [wortmannin inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Prazosin inhibits the reaction [carvedilol inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]
carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of NOS2 protein]

PMID:17159805 PMID:19439816 PMID:25245570

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

nitric oxide synthase 3

increases expression
multiple interactions
increases phosphorylation
decreases expression

carvedilol results in increased expression of NOS3 mRNA; carvedilol results in increased expression of NOS3 protein
Carvedilol inhibits the reaction [Doxorubicin results in decreased phosphorylation of NOS3 protein]
carvedilol results in increased phosphorylation of NOS3 protein
carvedilol results in decreased expression of NOS3 mRNA

PMID:16741616 PMID:17559835 PMID:18971572 PMID:31066085

NCBI chr 4:10,793,834...10,814,170
Ensembl chr 4:10,793,834...10,814,166

G

NADPH oxidase 1

multiple interactions

carvedilol inhibits the reaction [Doxorubicin results in increased expression of NOX1 mRNA]

NCBI chr X:97,279,058...97,332,291
Ensembl chr X:97,279,056...97,302,236

G

natriuretic peptide A

decreases expression
increases expression
decreases degradation
multiple interactions

carvedilol results in decreased expression of NPPA protein
carvedilol results in increased expression of NPPA mRNA; carvedilol results in increased expression of NPPA protein
carvedilol results in decreased expression of NPPA mRNA
carvedilol results in decreased degradation of NPPA protein
carvedilol inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; carvedilol promotes the reaction [NPPA protein results in increased abundance of Cyclic GMP]

PMID:1378157 PMID:9421401 PMID:10722803 PMID:11206715 PMID:21216836

NCBI chr 5:158,429,042...158,430,351
Ensembl chr 5:158,429,042...158,430,351

G

natriuretic peptide B

multiple interactions
decreases expression
increases expression

[carvedilol co-treated with temocapril hydrochloride co-treated with Spironolactone co-treated with Aspirin] affects the expression of NPPB protein
carvedilol inhibits the reaction [Doxorubicin results in increased expression of NPPB protein]
carvedilol results in decreased expression of NPPB protein
carvedilol results in decreased expression of NPPB mRNA; carvedilol results in decreased expression of NPPB protein
carvedilol results in increased expression of NPPB mRNA

PMID:11206715 PMID:19367012 PMID:19650993 PMID:19692266 PMID:20413026 More...

NCBI chr 5:158,416,813...158,418,175
Ensembl chr 5:158,416,866...158,418,168

G

natriuretic peptide receptor 3

decreases expression

carvedilol results in decreased expression of NPR3 mRNA

PMID:9421401 PMID:11206715

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:60,870,594...60,932,955

G

nuclear receptor subfamily 0, group B, member 2

decreases expression

Carvedilol results in decreased expression of NR0B2 mRNA

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

increases expression

Carvedilol results in increased expression of NR1H4 mRNA

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

oxidized low density lipoprotein receptor 1

multiple interactions

carvedilol inhibits the reaction [Doxorubicin results in increased expression of OLR1 mRNA]; carvedilol inhibits the reaction [Doxorubicin results in increased expression of OLR1 protein]; carvedilol inhibits the reaction [Hydrogen Peroxide results in increased expression of OLR1 mRNA]; carvedilol inhibits the reaction [Hydrogen Peroxide results in increased expression of OLR1 protein]

NCBI chr 4:162,926,436...162,949,057
Ensembl chr 4:162,926,439...162,948,523

G

platelet derived growth factor subunit B

multiple interactions

carvedilol results in decreased susceptibility to [PDGFB protein binds to PDGFB protein]

NCBI chr 7:111,539,444...111,557,984
Ensembl chr 7:111,540,345...111,557,984

G

phosphogluconate dehydrogenase

multiple interactions

carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD protein]

NCBI chr 5:159,582,746...159,598,945
Ensembl chr 5:159,561,271...159,742,778

G

peroxisome proliferator activated receptor alpha

multiple interactions

carvedilol inhibits the reaction [Ethanol results in decreased expression of PPARA mRNA]

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

PPARG coactivator 1 alpha

increases expression

carvedilol results in increased expression of PPARGC1A mRNA

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase C, alpha

decreases expression

carvedilol results in decreased expression of PRKCA protein

NCBI chr10:92,889,390...93,288,013
Ensembl chr10:92,894,012...93,288,012

G

protein kinase C, delta

decreases expression

carvedilol results in decreased expression of PRKCD protein

NCBI chr16:5,769,217...5,799,380
Ensembl chr16:5,769,215...5,799,352

G

protein kinase C, epsilon

increases activity

carvedilol results in increased activity of PRKCE protein

NCBI chr 6:7,965,048...8,451,966
Ensembl chr 6:7,965,048...8,451,719

G

platelet-activating factor receptor

multiple interactions

Carvedilol inhibits the reaction [Arginine results in increased expression of PTAFR mRNA]

NCBI chr 5:144,765,770...144,795,057
Ensembl chr 5:144,765,976...144,795,251

G

prostaglandin-endoperoxide synthase 1

decreases expression

carvedilol results in decreased expression of PTGS1 mRNA

NCBI chr 3:19,584,015...19,605,589
Ensembl chr 3:19,584,015...19,605,586

G

Rac family small GTPase 1

multiple interactions

carvedilol inhibits the reaction [AGT protein affects the localization of RAC1 protein]

NCBI chr12:11,037,028...11,057,251
Ensembl chr12:11,036,698...11,057,251

G

regenerating family member 3 beta

multiple interactions

Carvedilol inhibits the reaction [Arginine results in increased expression of REG3B mRNA]

NCBI chr 4:110,861,775...110,865,015
Ensembl chr 4:110,861,775...110,865,015

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Carvedilol inhibits the reaction [Arginine results in increased expression of RELA protein]; Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased phosphorylation of RELA protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of RELA protein]; Carvedilol inhibits the reaction [Potassium Dichromate affects the localization of RELA protein]

PMID:25245570 PMID:26036690 PMID:30254303 PMID:32569593

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

renin

decreases expression
multiple interactions

carvedilol results in decreased expression of REN protein
[aliskiren co-treated with Carvedilol] inhibits the reaction [Isoproterenol results in increased activity of REN protein]; Carvedilol inhibits the reaction [Isoproterenol results in increased activity of REN protein]

PMID:2454358 PMID:26982530

NCBI chr13:44,796,260...44,807,491
Ensembl chr13:44,796,091...44,807,489

G

ryanodine receptor 2

affects activity
decreases activity
increases expression
multiple interactions
increases activity

carvedilol affects the activity of RYR2 protein; carvedilol analog affects the activity of RYR2 protein
Carvedilol results in decreased activity of RYR2 protein
carvedilol results in increased expression of RYR2 protein
[Huang Qi co-treated with carvedilol] results in increased expression of RYR2 mRNA
carvedilol promotes the reaction [Perindopril results in increased expression of RYR2 protein]; Perindopril promotes the reaction [carvedilol results in increased expression of RYR2 protein]
carvedilol results in increased expression of RYR2 mRNA
carvedilol results in increased activity of RYR2 protein
carvedilol inhibits the reaction [Isoproterenol results in increased phosphorylation of RYR2 protein]; carvedilol promotes the reaction [FKBP1B protein binds to RYR2 protein]

PMID:12743001 PMID:19620082 PMID:21743453 PMID:21924056 PMID:37850394

NCBI chr17:58,389,925...58,975,641
Ensembl chr17:58,389,925...58,975,142

G

S100 calcium binding protein A10

decreases expression

carvedilol results in decreased expression of S100A10 protein

NCBI chr 2:179,221,012...179,229,659
Ensembl chr 2:179,220,887...179,229,661

G

S100 calcium binding protein A11

decreases expression

carvedilol results in decreased expression of S100A11 protein

NCBI chr 2:179,191,688...179,197,098
Ensembl chr 2:179,191,715...179,197,044

G

S100 calcium binding protein A6

decreases expression

carvedilol results in decreased expression of S100A6 protein

NCBI chr 2:176,100,619...176,102,181
Ensembl chr 2:176,100,899...176,102,180

G

serpin family H member 1

multiple interactions

carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 protein]

NCBI chr 1:153,643,500...153,650,853
Ensembl chr 1:153,643,510...153,650,801

G

solute carrier family 10 member 1

decreases expression
multiple interactions

Carvedilol results in decreased expression of SLC10A1 protein
[Carvedilol co-treated with Albuterol] results in decreased expression of SLC10A1 protein; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 mRNA]; Carvedilol inhibits the reaction [Albuterol results in increased expression of SLC10A1 protein]

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 22 member 1

multiple interactions

carvedilol inhibits the reaction [SLC22A1 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]

NCBI chr 1:48,076,657...48,103,679
Ensembl chr 1:48,076,666...48,103,678

G

solute carrier family 22 member 2

multiple interactions

Carvedilol inhibits the reaction [SLC22A2 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Carvedilol inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]; Carvedilol inhibits the reaction [SLC22A2 protein results in increased uptake of Metformin]

PMID:19740083 PMID:21599003

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

G

solute carrier family 22 member 3

multiple interactions

carvedilol inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; carvedilol inhibits the reaction [SLC22A3 protein results in increased uptake of Metformin]

PMID:21641380 PMID:21697722

NCBI chr 1:48,235,476...48,324,617
Ensembl chr 1:48,235,476...48,324,612

G

solute carrier family 22 member 4

multiple interactions

carvedilol inhibits the reaction [SLC22A4 protein results in increased uptake of Tetraethylammonium]

NCBI chr10:38,133,333...38,179,932
Ensembl chr10:38,133,322...38,179,720

G

SMAD family member 7

multiple interactions

Carvedilol inhibits the reaction [Carbon Tetrachloride results in decreased expression of SMAD7 protein]

NCBI chr18:68,988,429...69,016,774
Ensembl chr18:68,988,429...69,016,765

G

superoxide dismutase 1

multiple interactions

Carvedilol inhibits the reaction [Isoproterenol results in decreased expression of and results in decreased activity of SOD1 protein]

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions

carvedilol inhibits the reaction [Doxorubicin results in decreased expression of SOD2 protein]

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

SRY-box transcription factor 2

increases expression

carvedilol results in increased expression of SOX2 mRNA

NCBI chr 2:117,536,929...117,539,340
Ensembl chr 2:117,536,929...117,539,338

G

sperm microtubule inner protein 11

increases expression

Carvedilol results in increased expression of NPHS1

NCBI chr 7:129,720,950...129,742,485
Ensembl chr 7:129,720,950...129,742,485

G

sterol regulatory element binding transcription factor 1

multiple interactions

carvedilol inhibits the reaction [Ethanol results in increased expression of SREBF1 mRNA]

NCBI chr10:45,007,637...45,029,650
Ensembl chr10:45,007,637...45,029,650

G

signal transducer and activator of transcription 1

multiple interactions

Carvedilol inhibits the reaction [Arginine results in increased expression of STAT1 protein]

NCBI chr 9:49,419,561...49,459,969
Ensembl chr 9:49,419,340...49,588,540

G

telomeric repeat binding factor 2

affects expression

carvedilol affects the expression of TERF2 protein

NCBI chr19:34,976,963...35,005,813
Ensembl chr19:34,977,471...35,005,819

G

tissue factor pathway inhibitor

multiple interactions

[irbesartan co-treated with carvedilol] results in decreased expression of TFPI mRNA; [irbesartan co-treated with carvedilol] results in decreased expression of TFPI protein

NCBI chr 3:69,533,156...69,582,547
Ensembl chr 3:69,533,156...69,576,880

G

transforming growth factor, beta 1

decreases expression
decreases expression
multiple interactions

carvedilol results in decreased expression of TGFB1 mRNA
carvedilol decreases expression of TGFbeta mRNA in kidney of high fat high sodium diet fed SHRSP/A3N rats
carvedilol results in decreased expression of TGFB1 mRNA; carvedilol results in decreased expression of TGFB1 protein
Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of TGFB1 protein]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TGFB1 mRNA]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TGFB1 protein]; Carvedilol inhibits the reaction [Sodium, Dietary results in increased expression of TGFB1 mRNA]

CTD
RGD

PMID:11682445 PMID:11688356 PMID:12227681 PMID:15921778 PMID:16310260 More...

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tyrosine hydroxylase

multiple interactions
decreases expression

carvedilol inhibits the reaction [Ethanol results in increased expression of TH protein]
carvedilol results in decreased expression of TH mRNA; carvedilol results in decreased expression of TH protein

PMID:20359859 PMID:22413959

NCBI chr 1:198,071,500...198,078,832
Ensembl chr 1:198,071,503...198,109,767

G

TIMP metallopeptidase inhibitor 1

multiple interactions
decreases expression

carvedilol inhibits the reaction [Ethanol results in increased expression of TIMP1 mRNA]; carvedilol inhibits the reaction [Ethanol results in increased expression of TIMP1 protein]
carvedilol results in decreased expression of TIMP1 mRNA

PMID:21216836 PMID:22413959

NCBI chr X:1,212,969...1,217,714
Ensembl chr X:1,212,972...1,217,664

G

tumor necrosis factor

multiple interactions
decreases expression

carvedilol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]; carvedilol inhibits the reaction [TNF protein results in increased expression of MMP2 protein]; carvedilol inhibits the reaction [TNF protein results in increased expression of MMP9 protein]
carvedilol results in decreased expression of TNF mRNA; carvedilol results in decreased expression of TNF protein
Carvedilol inhibits the reaction [Arginine results in increased expression of TNF protein]; Carvedilol inhibits the reaction [Doxorubicin results in increased expression of TNF protein]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TNF mRNA]; Carvedilol inhibits the reaction [Ethanol results in increased expression of TNF protein]; Carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of TNF protein]

PMID:15229385 PMID:16310260 PMID:17964422 PMID:20017808 PMID:22413959 More...

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

affects expression
multiple interactions

carvedilol affects the expression of TP53 protein
carvedilol inhibits the reaction [Potassium Dichromate results in increased expression of TP53 protein]

PMID:22000973 PMID:25245570

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

G

thioredoxin 1

increases expression

carvedilol results in increased expression of TXN1 protein

NCBI chr 5:72,712,334...72,724,564
Ensembl chr 5:72,711,933...72,724,629

G

UDP glucuronosyltransferase family 1 member A1

increases glucuronidation
affects metabolic processing
affects glucuronidation

UGT1A1 protein results in increased glucuronidation of carvedilol
UGT1A1 gene polymorphism affects the metabolism of carvedilol
UGT1A1 gene polymorphism affects the glucuronidation of carvedilol

PMID:14744946 PMID:16849011

NCBI chr 9:88,801,344...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

UDP glucuronosyltransferase family 2 member B7

increases glucuronidation
affects glucuronidation
affects metabolic processing

UGT2B7 protein results in increased glucuronidation of carvedilol
UGT2B7 gene polymorphism affects the glucuronidation of carvedilol
UGT2B7 gene polymorphism affects the metabolism of carvedilol

PMID:14744946 PMID:16849011 PMID:17329852

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:20,896,682...20,919,604

G

vimentin

multiple interactions

Carvedilol inhibits the reaction [Carbon Tetrachloride results in increased expression of VIM protein]; Carvedilol inhibits the reaction [Streptozocin results in increased expression of VIM protein]

PMID:12140129 PMID:30254303

NCBI chr17:76,668,701...76,677,186
Ensembl chr17:76,668,647...76,677,187

CGP 12177

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 1

multiple interactions
affects binding
increases activity

[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP; [CGP 12177 binds to and results in decreased activity of ADRB1 protein] which results in decreased abundance of Cyclic AMP; [CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP; Alprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Bisoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Bisoprolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Bupranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 12177 binds to and results in decreased activity of ADRB1 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB1 protein]; CGP 12177 inhibits the reaction [Isoproterenol results in increased activity of ADRB1 protein]; CGP 20712A inhibits the reaction [[CGP 12177 co-treated with ADRB1] results in increased abundance of Cyclic AMP]; CGP 20712A inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Metoprolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nadolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Oxprenolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Pindolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [CGP 12177 results in increased activity of ADRB1 protein]; Sotalol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]; Timolol inhibits the reaction [[CGP 12177 binds to ADRB1 protein] which results in increased abundance of Cyclic AMP]
Atenolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; CGP 20712A inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Nebivolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB1 protein]

PMID:2462161 PMID:9593075 PMID:10217540 PMID:12535855 PMID:12761341 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

multiple interactions
affects binding

[CGP 12177 binds to and results in decreased activity of ADRB2 protein] which results in decreased abundance of Cyclic AMP; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; CGP 12177 binds to and results in decreased activity of ADRB2 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB2 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB2 protein]
Atenolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; carvedilol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; ICI 118551 inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Labetalol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Pindolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]; Propranolol inhibits the reaction [CGP 12177 binds to ADRB2 protein]

PMID:2462161 PMID:9593075 PMID:12535855 PMID:14730417 PMID:17628611 More...

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions
affects binding
increases activity
affects response to substance

[CGP 12177 binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; CGP 12177 binds to and results in increased activity of ADRB3 protein; CGP 12177 inhibits the reaction [cyanopindolol binds to ADRB3 protein]; N-(3-hydroxy-1-(naphthalen-1-yl)-1,8,11-trioxa-5-azatridecan-13-yl)-6-(2-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)-4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxyacetamido)hexanamide inhibits the reaction [CGP 12177 binds to ADRB3 protein]
CGP 12177 results in increased activity of ADRB3 protein
ADRB3 affects the susceptibility to CGP 12177
3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [CGP 12177 results in increased activity of ADRB3 protein]; CGP 12177 binds to and results in increased activity of ADRB3 protein

PMID:7815362 PMID:8569714 PMID:10217540 PMID:10952688 PMID:11159692 More...

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

CF transmembrane conductance regulator

multiple interactions
increases activity

2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; Pertussis Toxin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; U 0126 inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]; wortmannin inhibits the reaction [CGP 12177 results in increased activity of CFTR protein]

NCBI chr 4:46,561,269...46,728,759
Ensembl chr 4:46,560,885...46,728,756

G

growth hormone 1

multiple interactions

GH1 protein promotes the reaction [CGP 12177 results in increased metabolism of Lipids]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

lipoprotein lipase

increases expression

CGP 12177 results in increased expression of LPL mRNA

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

mitogen activated protein kinase 1

increases activity

CGP 12177 results in increased activity of MAPK1 protein

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

increases activity

CGP 12177 results in increased activity of MAPK3 protein

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

upstream transcription factor 1

multiple interactions

USF1 gene polymorphism promotes the reaction [CGP 12177 results in increased metabolism of Lipids]; USF1 protein affects the reaction [CGP 12177 results in increased metabolism of Lipids]

NCBI chr13:83,845,230...83,854,875
Ensembl chr13:83,822,035...83,854,885

G

vascular endothelial growth factor A

increases expression

CGP 12177 results in increased expression of VEGFA mRNA

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

clenbuterol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

acyl-CoA dehydrogenase medium chain

increases expression

Clenbuterol results in increased expression of ACADM mRNA

NCBI chr 2:242,858,865...242,883,036
Ensembl chr 2:242,858,865...242,883,147

G

adrenoceptor beta 2

multiple interactions
increases activity

[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose; ICI 118551 inhibits the reaction [[Clenbuterol binds to and results in increased activity of ADRB2 protein] which results in decreased uptake of Glucose]
Clenbuterol results in increased activity of ADRB2 protein

PMID:16007677 PMID:18552870 PMID:34601065

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

Clenbuterol binds to and results in increased activity of ADRB3 protein

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

AKT serine/threonine kinase 1

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

AKT serine/threonine kinase 3

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A1 protein]]

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [Lipopolysaccharides results in decreased activity of CYP1A2 protein]]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

estrogen related receptor, alpha

increases expression

Clenbuterol results in increased expression of ESRRA mRNA

NCBI chr 1:204,104,100...204,114,182
Ensembl chr 1:204,104,101...204,114,268

G

glutamate decarboxylase 1

multiple interactions

Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]; Clenbuterol inhibits the reaction [Reserpine results in increased expression of GAD1 mRNA]; Propranolol inhibits the reaction [Clenbuterol inhibits the reaction [3-acetylpyridine results in increased expression of GAD1 mRNA]]

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:55,369,704...55,410,333

G

interleukin 10

multiple interactions
affects expression

Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein]
Clenbuterol affects the expression of IL10 protein

PMID:15021963 PMID:15502056

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 18

increases expression

Clenbuterol results in increased expression of IL18 mRNA; Clenbuterol results in increased expression of IL18 protein

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL1B protein]

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

NFKB inhibitor alpha

multiple interactions

Clenbuterol inhibits the reaction [Tetradecanoylphorbol Acetate results in increased degradation of NFKBIA protein]

NCBI chr 6:72,858,713...72,861,941
Ensembl chr 6:72,858,712...72,861,941

G

ornithine decarboxylase 1

multiple interactions
increases stability
increases activity

Alprenolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Metoprolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]; Propranolol inhibits the reaction [Clenbuterol results in increased activity of ODC1 protein]
Clenbuterol results in increased stability of ODC1 protein

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:40,329,964...40,336,440

G

pyruvate dehydrogenase kinase 4

increases expression

Clenbuterol results in increased expression of PDK4 mRNA

NCBI chr 4:33,591,796...33,601,798
Ensembl chr 4:33,589,799...33,601,850

G

PPARG coactivator 1 alpha

increases expression
multiple interactions

Clenbuterol results in increased expression of PPARGC1A mRNA
Propranolol inhibits the reaction [Clenbuterol results in increased expression of PPARGC1A mRNA]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

protein kinase cAMP-activated catalytic subunit alpha

multiple interactions

Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]

NCBI chr19:24,155,081...24,178,430
Ensembl chr19:24,155,090...24,178,430

G

RELA proto-oncogene, NF-kB subunit

multiple interactions

Clenbuterol affects the reaction [Lipopolysaccharides affects the localization of RELA protein]

NCBI chr 1:202,925,001...202,935,484
Ensembl chr 1:202,924,945...202,935,484

G

transcription factor A, mitochondrial

increases expression

Clenbuterol results in increased expression of TFAM mRNA

NCBI chr20:17,356,243...17,368,293
Ensembl chr20:17,356,197...17,368,292

G

tumor necrosis factor

multiple interactions

Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF mRNA]; Clenbuterol inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein]

PMID:15021963 PMID:15710352

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

uncoupling protein 1

increases expression

Clenbuterol results in increased expression of UCP1 protein

NCBI chr19:24,808,782...24,816,853
Ensembl chr19:24,808,783...24,816,852

clorprenaline

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

adrenoceptor beta 2

increases activity

clorprenaline results in increased activity of ADRB2 protein

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

solute carrier family 22 member 2

multiple interactions

clorprenaline inhibits the reaction [SLC22A2 protein results in increased uptake of 4-(4-dimethylaminostyryl)-1-methylpyridinium]

NCBI chr 1:48,121,061...48,163,268
Ensembl chr 1:48,121,061...48,163,268

diazoxide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

actin alpha 2, smooth muscle

multiple interactions

5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]]; Diazoxide inhibits the reaction [Bleomycin results in increased expression of ACTA2 protein]

NCBI chr 1:231,746,527...231,759,307
Ensembl chr 1:231,746,548...231,759,554

G

apoptosis inducing factor, mitochondria associated 1

decreases localization
multiple interactions

Diazoxide results in decreased localization of AIFM1 protein
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Bleomycin affects the expression of and affects the localization of AIFM1 protein]]; Diazoxide inhibits the reaction [Bleomycin affects the expression of and affects the localization of AIFM1 protein]
5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in decreased localization of AIFM1 protein]

PMID:21256120 PMID:37783230

NCBI chr X:127,650,223...127,689,356
Ensembl chr X:127,650,226...127,689,256

G

AKT serine/threonine kinase 1

multiple interactions
increases phosphorylation

5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased phosphorylation of AKT1 protein]

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

BCL2 associated X, apoptosis regulator

multiple interactions

Diazoxide inhibits the reaction [Streptozocin results in increased expression of BAX protein]
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Bleomycin results in increased expression of BAX protein]]; Diazoxide inhibits the reaction [Bleomycin results in increased expression of BAX protein]

PMID:20650802 PMID:37783230

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

multiple interactions

Diazoxide inhibits the reaction [Streptozocin results in decreased expression of BCL2 protein]
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Bleomycin results in decreased expression of BCL2 protein]]; Diazoxide inhibits the reaction [Bleomycin results in decreased expression of BCL2 protein]

PMID:20650802 PMID:37783230

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

multiple interactions
increases expression

5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased expression of BCL2L1 mRNA alternative form]; 5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased expression of BCL2L1 protein alternative form]
Diazoxide results in increased expression of BCL2L1 mRNA alternative form; Diazoxide results in increased expression of BCL2L1 protein alternative form

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

caspase 3

multiple interactions
decreases activity

5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in decreased activity of CASP3 protein]

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

cyclin D1

multiple interactions
decreases expression

Diazoxide inhibits the reaction [CTNNB1 protein results in increased activity of CCND1 promoter]
Diazoxide results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

collagen type I alpha 1 chain

multiple interactions

5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]]; Diazoxide inhibits the reaction [Bleomycin results in increased expression of COL1A1 protein]

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

catenin beta 1

multiple interactions
decreases expression

Diazoxide inhibits the reaction [CTNNB1 protein results in increased activity of CCND1 promoter]
Diazoxide results in decreased expression of CTNNB1 protein

NCBI chr 8:120,640,008...120,667,110
Ensembl chr 8:120,639,995...120,667,111

G

cytochrome c, somatic

decreases secretion
multiple interactions

Diazoxide results in decreased secretion of CYCS protein
5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in decreased secretion of CYCS protein]

NCBI chr 4:79,651,894...79,653,994
Ensembl chr 4:79,651,378...79,654,054
Ensembl chr18:79,651,378...79,654,054

G

Fms related receptor tyrosine kinase 1

multiple interactions

5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]; Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]; HMOX1 protein affects the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]; zinc protoporphyrin inhibits the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:7,297,292...7,468,626

G

glucagon

multiple interactions

Diazoxide inhibits the reaction [gatifloxacin results in increased secretion of GCG protein]

NCBI chr 3:47,113,914...47,122,958
Ensembl chr 3:47,113,914...47,122,929

G

glycerol-3-phosphate dehydrogenase 2

multiple interactions

[Potassium Chloride co-treated with Diazoxide] inhibits the reaction [[GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]

NCBI chr 3:41,800,552...41,937,729
Ensembl chr 3:41,801,930...41,936,901

G

heme oxygenase 1

multiple interactions

Diazoxide inhibits the reaction [Oxygen deficiency results in decreased expression of HMOX1 mRNA]; Diazoxide inhibits the reaction [Oxygen deficiency results in decreased expression of HMOX1 protein]; HMOX1 protein affects the reaction [Diazoxide inhibits the reaction [Oxygen deficiency results in increased expression of FLT1 protein]]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

islet amyloid polypeptide

multiple interactions

Diazoxide inhibits the reaction [Glucose results in increased expression of IAPP mRNA]

NCBI chr 4:175,237,107...175,244,373
Ensembl chr 4:175,237,115...175,242,920

G

interleukin 10

decreases secretion

Diazoxide results in decreased secretion of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 6

decreases secretion

Diazoxide results in decreased secretion of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

insulin 1

multiple interactions

[Potassium Chloride co-treated with Diazoxide] inhibits the reaction [[GPD2 mutant form co-treated with Aminooxyacetic Acid] inhibits the reaction [Glucose results in increased secretion of INS1 protein]]
Diazoxide inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]; Diazoxide inhibits the reaction [Bezafibrate results in decreased expression of INS1 mRNA]

PMID:10464266 PMID:10780946 PMID:11527545

NCBI chr 1:251,244,973...251,245,540
Ensembl chr 1:251,244,973...251,245,536

G

insulin 2

multiple interactions

Diazoxide inhibits the reaction [Glucose results in increased secretion of INS protein]

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

potassium inwardly-rectifying channel, subfamily J, member 11

decreases expression

Diazoxide results in decreased expression of KCNJ11 mRNA

NCBI chr 1:96,591,048...96,594,574
Ensembl chr 1:96,591,049...96,594,082

G

leptin

multiple interactions
decreases secretion

Diazoxide inhibits the reaction [[Glucose co-treated with INS1 protein] results in increased secretion of LEP protein]
Diazoxide results in decreased secretion of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

nicotinamide phosphoribosyltransferase

multiple interactions

Diazoxide inhibits the reaction [Glucose results in increased secretion of NAMPT protein]

NCBI chr 6:49,425,316...49,462,109
Ensembl chr 6:49,424,332...49,462,100

G

nuclear factor kappa B subunit 1

multiple interactions
increases activity

5-hydroxydecanoic acid inhibits the reaction [Diazoxide results in increased activity of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

nitric oxide synthase 2

multiple interactions

5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased expression of and results in increased activity of NOS2 protein]]; Diazoxide inhibits the reaction [Rotenone results in increased expression of and results in increased activity of NOS2 protein]
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased activity of NOS2 protein]]; 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased expression of NOS2 mRNA]]; Diazoxide inhibits the reaction [Rotenone results in increased activity of NOS2 protein]; Diazoxide inhibits the reaction [Rotenone results in increased expression of NOS2 mRNA]

PMID:15795934 PMID:15927086 PMID:16257489

NCBI chr10:63,815,308...63,851,208
Ensembl chr10:63,815,308...63,851,210

G

pancreatic and duodenal homeobox 1

multiple interactions

Diazoxide inhibits the reaction [Bezafibrate results in decreased expression of PDX1 mRNA]

NCBI chr12:7,757,865...7,763,064
Ensembl chr12:7,757,865...7,763,064

G

solute carrier family 2 member 2

multiple interactions

Diazoxide inhibits the reaction [Bezafibrate results in decreased expression of SLC2A2 mRNA]

NCBI chr 2:111,609,798...111,639,930
Ensembl chr 2:111,611,774...111,639,933

G

transforming growth factor, beta 1

multiple interactions

5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]]; Diazoxide inhibits the reaction [Bleomycin results in increased expression of TGFB1 protein]

NCBI chr 1:81,196,532...81,212,848
Ensembl chr 1:81,196,532...81,212,847

G

tumor necrosis factor

decreases secretion
multiple interactions

Diazoxide results in decreased secretion of TNF protein
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]]; 5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased expression of TNF protein]]; Diazoxide inhibits the reaction [1-Methyl-4-phenylpyridinium results in increased secretion of TNF protein]; Diazoxide inhibits the reaction [Rotenone results in increased expression of TNF protein]
5-hydroxydecanoic acid inhibits the reaction [Diazoxide inhibits the reaction [Rotenone results in increased secretion of TNF protein]]; Diazoxide inhibits the reaction [Rotenone results in increased secretion of TNF protein]

PMID:16257489 PMID:16612254 PMID:18700057 PMID:19012619

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

tumor protein p53

decreases expression

Diazoxide results in decreased expression of TP53 mRNA

NCBI chr10:54,300,070...54,311,525
Ensembl chr10:54,300,048...54,311,524

dobutamine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

decreases activity

Dobutamine results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

adenylate cyclase 6

affects response to substance

ADCY6 protein affects the susceptibility to Dobutamine

NCBI chr 7:129,742,827...129,763,922
Ensembl chr 7:129,742,838...129,763,754

G

adrenoceptor alpha 2A

multiple interactions

Dobutamine binds to and results in increased activity of ADRA2A protein

NCBI chr 1:253,061,480...253,064,280
Ensembl chr 1:253,060,218...253,064,365

G

adrenoceptor beta 1

affects response to substance
multiple interactions

ADRB1 gene affects the susceptibility to Dobutamine; ADRB1 gene polymorphism affects the susceptibility to Dobutamine; ADRB1 protein polymorphism affects the susceptibility to Dobutamine
[Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Oxygen deficiency results in increased susceptibility to [Dobutamine binds to and results in increased activity of ADRB1 protein]
ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

PMID:8096834 PMID:10192281 PMID:11753577 PMID:14502278 PMID:15564877 More...

NCBI chr 1:255,771,962...255,774,973
Ensembl chr 1:255,771,597...255,807,259

G

adrenoceptor beta 2

affects response to substance

ADRB2 gene polymorphism affects the susceptibility to Dobutamine

NCBI chr18:55,642,459...55,644,501
Ensembl chr18:55,502,903...55,644,512

G

adrenoceptor beta 3

multiple interactions

[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein

NCBI chr16:64,839,820...64,844,552
Ensembl chr16:64,841,788...64,844,552

G

alpha-2-HS-glycoprotein

affects response to substance

AHSG protein affects the susceptibility to Dobutamine

NCBI chr11:78,121,388...78,127,998
Ensembl chr11:78,117,918...78,145,999

G

AKT serine/threonine kinase 1

affects response to substance
multiple interactions

AKT1 protein affects the susceptibility to Dobutamine
Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]

PMID:16094411 PMID:16339297

NCBI chr 6:131,713,716...131,735,319
Ensembl chr 6:131,713,720...131,733,921

G

AKT serine/threonine kinase 2

multiple interactions

Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]

NCBI chr 1:82,877,228...82,933,828
Ensembl chr 1:82,883,547...82,933,817

G

AKT serine/threonine kinase 3

multiple interactions

Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]

NCBI chr13:88,943,708...89,225,831
Ensembl chr13:88,946,091...89,225,708

G

arrestin, beta 1

multiple interactions

ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

NCBI chr 1:153,837,964...153,912,111
Ensembl chr 1:153,838,078...153,904,061

G

arrestin, beta 2

multiple interactions

ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]

NCBI chr10:55,146,887...55,154,854
Ensembl chr10:55,146,818...55,154,850

G

BCL2 associated X, apoptosis regulator

increases expression

Dobutamine results in increased expression of BAX protein

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

decreases expression

Dobutamine results in decreased expression of BCL2 protein

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

BCL2 interacting protein 1

increases expression

Dobutamine results in increased expression of BNIP1 protein

NCBI chr10:16,386,876...16,399,124
Ensembl chr10:16,386,841...16,399,157

G

C-C motif chemokine ligand 2

multiple interactions

Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 3

multiple interactions

Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 protein]

NCBI chr10:68,451,388...68,452,938
Ensembl chr10:68,451,388...68,452,938

G

clusterin

increases expression

Dobutamine results in increased expression of CLU protein

NCBI chr15:40,161,068...40,200,315
Ensembl chr15:40,174,617...40,200,315

G

catechol-O-methyltransferase

increases methylation
increases expression

COMT protein results in increased methylation of Dobutamine
Dobutamine results in increased expression of COMT mRNA

PMID:11160877 PMID:12423672

NCBI chr11:82,568,052...82,587,642
Ensembl chr11:82,568,025...82,587,642

G

carnitine palmitoyltransferase 1A

increases expression

Dobutamine results in increased expression of CPT1A mRNA; Dobutamine results in increased expression of CPT1A protein

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

cAMP responsive element modulator

affects response to substance

CREM protein affects the susceptibility to Dobutamine

NCBI chr17:54,238,889...54,305,989
Ensembl chr17:54,239,030...54,305,989

G

cardiotrophin 1

affects response to substance

CTF1 protein affects the susceptibility to Dobutamine

NCBI chr 1:182,328,035...182,336,346
Ensembl chr 1:182,328,090...182,333,335

G

C-X-C motif chemokine ligand 2

multiple interactions

Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CXCL2 mRNA]

NCBI chr14:17,181,030...17,183,075
Ensembl chr14:17,181,062...17,183,075

G

dopamine beta-hydroxylase

affects response to substance

DBH protein affects the susceptibility to Dobutamine

NCBI chr 3:10,488,260...10,505,245
Ensembl chr 3:10,488,260...10,505,248

G

dystrophin

increases response to substance

DMD gene mutant form results in increased susceptibility to Dobutamine

NCBI chr X:47,272,324...49,504,219
Ensembl chr X:47,272,331...49,504,207

G

epidermal growth factor receptor

decreases response to substance
multiple interactions

EGFR gene mutant form results in decreased susceptibility to Dobutamine
AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]

PMID:18599591 PMID:18787115

NCBI chr14:91,176,979...91,349,722
Ensembl chr14:91,177,067...91,344,382

G

estrogen receptor 1

multiple interactions

Dobutamine binds to and results in increased activity of ESR1 protein

NCBI chr 1:41,106,335...41,499,104
Ensembl chr 1:41,210,475...41,495,002

G

coagulation factor III, tissue factor

increases expression

Dobutamine results in increased expression of F3 protein

NCBI chr 2:209,827,061...209,838,666
Ensembl chr 2:209,826,959...209,838,668

G

fibroblast growth factor 2

affects response to substance

FGF2 protein affects the susceptibility to Dobutamine

PMID:10491406 PMID:14583313

NCBI chr 2:120,236,328...120,290,673
Ensembl chr 2:120,236,328...120,291,221

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

glucose-6-phosphate dehydrogenase

increases activity

Dobutamine results in increased activity of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth hormone 1

multiple interactions

GH1 protein promotes the reaction [Dobutamine results in increased metabolism of Lipids]

NCBI chr10:91,228,102...91,230,079
Ensembl chr10:91,228,103...91,230,078

G

glycerol kinase

increases activity

Dobutamine results in increased activity of GK protein

NCBI chr X:50,162,089...50,238,707
Ensembl chr X:50,163,123...50,238,631

G

GNAS complex locus

increases response to substance

GNAS gene SNP results in increased susceptibility to Dobutamine

NCBI chr 3:163,071,003...163,136,350
Ensembl chr 3:163,071,417...163,127,262
Ensembl chr 3:163,071,417...163,127,262

G

glycogen synthase kinase 3 beta

affects response to substance

GSK3B gene mutant form affects the susceptibility to Dobutamine

NCBI chr11:62,498,997...62,648,665
Ensembl chr11:62,504,316...62,648,646

G